[
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 9296617
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171608",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000171608 at this locus (355116bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 9348900
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Response to tocilizumab in rheumatoid arthritis [CSJC , EA, RF-]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European, Other=1157"
      ],
      "otg_id": "GCST001476_7",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST001476",
      "pubmed_id": "22491018"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171608",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000171608 at this locus (302833bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 26811902
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) [AA]",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=488",
        "African American or Afro-Caribbean=111",
        "Hispanic or Latin American=60",
        "Other=56"
      ],
      "otg_id": "GCST004250_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST004250",
      "pubmed_id": "28090653"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169442",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "CAMPATH-1 antigen inhibitor drug ALEMTUZUMAB is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000169442 at this locus (491379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43572014
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (419487bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43631859
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43631859
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43631859
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43631859
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43634413
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 43634413
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196517",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 46135245
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 7.530472520812986,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117480",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Anandamide amidohydrolase inhibitor drug ACETAMINOPHEN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000117480 at this locus (259073bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55021673
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 28.214189147749966,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55021673
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 28.214189147749966,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55021673
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 28.214189147749966,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 11.88941028970075,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 12.71669877129645,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 11.88941028970075,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 12.71669877129645,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003774"
      ],
      "reported_trait_name": "Hyperlipidemia",
      "standard_trait_name": "hyperlipidemia"
    },
    "association_info": {
      "ancestry": [
        "European=408878"
      ],
      "otg_id": "SAIGE_272_1",
      "neg_log_pval": 12.79860287567955,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55023869
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 11.88941028970075,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55030366
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (9183bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003774"
      ],
      "reported_trait_name": "Hyperlipidemia",
      "standard_trait_name": "hyperlipidemia"
    },
    "association_info": {
      "ancestry": [
        "European=408878"
      ],
      "otg_id": "SAIGE_272_1",
      "neg_log_pval": 23.57186520597121,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 20.25103713874384,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 24.69897000433602,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 11.844663962534938,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 20.25103713874384,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 20.25103713874384,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 64.89219328560758,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 64.89219328560758,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 21.731656086048936,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 17.82390874094432,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 23.614393726401687,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 23.614393726401687,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 64.89219328560758,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55039974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55055640
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 14.0,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55055640
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 14.0,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 55055640
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 14.0,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169174",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 62582606
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 7.812479279163537,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132855",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (14882bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 62655430
      },
      "alleles": {
        "reference": "T",
        "alternative": "TC"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 24.119709018294724,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132855",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (49271bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 65513597
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity (early onset extreme)",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=6889"
      ],
      "otg_id": "GCST001957",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST001957",
      "pubmed_id": "23563609"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000116678",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Leptin receptor agonist drug METRELEPTIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000116678 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 100941963
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=26621"
      ],
      "otg_id": "GCST001198",
      "neg_log_pval": 9.426548177964515,
      "gwas_catalog_id": "GCST001198",
      "pubmed_id": "21833088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000170989",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sphingosine 1-phosphate receptor Edg-1 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 100941963
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=26621"
      ],
      "otg_id": "GCST001198",
      "neg_log_pval": 9.426548177964515,
      "gwas_catalog_id": "GCST001198",
      "pubmed_id": "21833088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000170989",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sphingosine 1-phosphate receptor Edg-1 agonist drug PONESIMOD is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 116744732
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 14.221848749616356,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000116824",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-cell surface antigen CD2 inhibitor drug SIPLIZUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 116744732
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 14.221848749616356,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000116824",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "T-cell surface antigen CD2 inhibitor drug ALEFACEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150059494
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150059494
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150059494
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150143798
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (225954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150143798
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000159164 at this locus (225954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150685811
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000143387",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150685811
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000143387",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 150685811
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000143387",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 153689947
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 9.096910013008056,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169418",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169418 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 153689947
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 10.209025579976215,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169418",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169418 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [EA]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529_3",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 17.045757490560675,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [EA]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529_3",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 17.045757490560675,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154453788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154454494
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154454494
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=47580"
      ],
      "otg_id": "GCST005569",
      "neg_log_pval": 7.8807441107220635,
      "gwas_catalog_id": "GCST005569",
      "pubmed_id": "23143596"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154454494
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160712",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154861707
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160752",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 154861707
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160752",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 155157915
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160752",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Farnesyl diphosphate synthase inhibitor drug PAMIDRONIC ACID is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000160752 at this locus (150834bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 155176305
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 10.316502682320188,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160752",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 155176305
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 10.316502682320188,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160752",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Farnesyl diphosphate synthase inhibitor drug ALENDRONIC ACID is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 155176305
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 10.316502682320188,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000185499",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mucin-1 other drug HUHMFG1 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000185499 at this locus (9520bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 169498416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_7",
      "neg_log_pval": 33.801755413771765,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198734",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 169498416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Pulmonary embolism +/- dvt | non-cancer illness code, self-reported",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1093",
      "neg_log_pval": 34.79160702064111,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198734",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 169549811
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 136.39794000867204,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198734",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 172731728
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 7.340779989063745,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117586",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (452003bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 173162354
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117586",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (21377bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 173182897
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117586",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (834bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 173201479
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 8.202546175019036,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117586",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 173201479
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 8.11264155329629,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117586",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 174223264
      },
      "alleles": {
        "reference": "TAAAAAAAAAAAAAAAAA",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002506"
      ],
      "reported_trait_name": "Osteoarthritis",
      "standard_trait_name": "osteoarthritis"
    },
    "association_info": {
      "ancestry": [
        "European=455221"
      ],
      "otg_id": "GCST007093",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST007093",
      "pubmed_id": "30664745"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000117601",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Antithrombin-III activator drug HEPARIN SODIUM is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000117601 at this locus (305887bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 186906327
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 8.37190434327122,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000073756",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cyclooxygenase-2 inhibitor drug CELECOXIB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000073756 at this locus (225905bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203057086
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 19.006828394969236,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203057086
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 24.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203057463
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "East Asian=36792"
      ],
      "otg_id": "GCST004373",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST004373",
      "pubmed_id": "28416822"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33191bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203059583
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 9.97061622231479,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203059583
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 18.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203065778
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Early onset atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4372"
      ],
      "otg_id": "GCST004352",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST004352",
      "pubmed_id": "28460022"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (24876bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203122146
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 9.949848472659069,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203124073
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203131376
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 203134077
      },
      "alleles": {
        "reference": "T",
        "alternative": "TA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 9.000392345087638,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163485",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 215131342
      },
      "alleles": {
        "reference": "TATA",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.172660456455034,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082482",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 2 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000082482 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 217047232
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 8.408601448718752,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196482",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen-related receptor gamma antagonist drug AFIMOXIFENE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000196482 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 239737706
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000133019",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M3 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "1",
        "position": 239737706
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000133019",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M3 antagonist drug AZD8683 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 5742188
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000134460 at this locus (268502bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6039267
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 12.095825631715837,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6050383
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=4421"
      ],
      "otg_id": "GCST004290",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST004290",
      "pubmed_id": "28445677"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6051176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 14.096910013008056,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6051176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 17.69897000433602,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6051176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 8.749579997691106,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6051176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 13.823908740944319,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16179"
      ],
      "otg_id": "GCST001394",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001394",
      "pubmed_id": "22293688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 7.702896349850744,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 38.54606892809315,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16179"
      ],
      "otg_id": "GCST001394",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001394",
      "pubmed_id": "22293688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=102453"
      ],
      "otg_id": "GCST007563",
      "neg_log_pval": 11.397940008672037,
      "gwas_catalog_id": "GCST007563",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 38.54606892809315,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 12.496209316942819,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6052734
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6055320
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=19102"
      ],
      "otg_id": "GCST001191",
      "neg_log_pval": 38.0,
      "gwas_catalog_id": "GCST001191",
      "pubmed_id": "21829393"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6055320
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=19102"
      ],
      "otg_id": "GCST001191",
      "neg_log_pval": 38.0,
      "gwas_catalog_id": "GCST001191",
      "pubmed_id": "21829393"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6056986
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6056986
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6056986
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6056986
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6056986
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6057082
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 22.11861534322943,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6059750
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=26621"
      ],
      "otg_id": "GCST001198",
      "neg_log_pval": 8.68909437062386,
      "gwas_catalog_id": "GCST001198",
      "pubmed_id": "21833088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6060049
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=21389"
      ],
      "otg_id": "GCST000879",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST000879",
      "pubmed_id": "21102463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6060049
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=5224"
      ],
      "otg_id": "GCST000062",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST000062",
      "pubmed_id": "17660530"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6060049
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=17698"
      ],
      "otg_id": "GCST001341",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST001341",
      "pubmed_id": "22190364"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6064589
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 22.81702340982209,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6064589
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 22.81702340982209,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6079323
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 20.443697499232712,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (16953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6080706
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=15283"
      ],
      "otg_id": "GCST003566",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003566",
      "pubmed_id": "27386562"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (18336bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6081532
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6081532
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6082294
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 17.190440285364733,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (19925bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6087680
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 8.257205214388867,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6087680
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 8.257205214388867,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6134203
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 8.018482423811946,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (71834bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6348488
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=8207"
      ],
      "otg_id": "GCST000258",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST000258",
      "pubmed_id": "18978792"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 6348488
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=8207"
      ],
      "otg_id": "GCST000258",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST000258",
      "pubmed_id": "18978792"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000134460",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48766611
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=18264",
        "African American or Afro-Caribbean=5422",
        "Hispanic or Latin American=3888"
      ],
      "otg_id": "GCST005752",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST005752",
      "pubmed_id": "28714469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (327251bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48817351
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5420"
      ],
      "otg_id": "GCST003599",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003599",
      "pubmed_id": "26663301"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48817351
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=14267"
      ],
      "otg_id": "GCST003155",
      "neg_log_pval": 10.065299598284575,
      "gwas_catalog_id": "GCST003155",
      "pubmed_id": "26502338"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48817351
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus [EA]",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5057",
        "European=10995"
      ],
      "otg_id": "GCST003622_3",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST003622",
      "pubmed_id": "27399966"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48817351
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=14267"
      ],
      "otg_id": "GCST003156",
      "neg_log_pval": 10.065299598284575,
      "gwas_catalog_id": "GCST003156",
      "pubmed_id": "26502338"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48817351
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1798"
      ],
      "otg_id": "GCST000592",
      "neg_log_pval": 11.096910013008056,
      "gwas_catalog_id": "GCST000592",
      "pubmed_id": "20169177"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48834906
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5050"
      ],
      "otg_id": "GCST001795",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST001795",
      "pubmed_id": "23273568"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (395547bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48893932
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=18264"
      ],
      "otg_id": "GCST007400",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST007400",
      "pubmed_id": "28714469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (454572bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 48911009
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2252"
      ],
      "otg_id": "GCST000507",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST000507",
      "pubmed_id": "19838193"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000107643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (471650bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 92672243
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000095596",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 26A1 inhibitor drug TALAROZOLE is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000095596 at this locus (401233bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 102654464
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000148795",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 102654464
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000148795",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 102654464
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 15.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000148795",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 102654464
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 15.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000148795",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 113963919
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.399595651036623,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug NADOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (80138bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 113982069
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug ACEBUTOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (61988bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114032303
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004329"
      ],
      "reported_trait_name": "Systolic blood pressure x alcohol consumption interaction (2df test) [EA]",
      "standard_trait_name": "alcohol drinking"
    },
    "association_info": {
      "ancestry": [
        "European=91102",
        "African American or Afro-Caribbean=21417",
        "Asian unspecified=12365",
        "Hispanic or Latin American=8471"
      ],
      "otg_id": "GCST006434_9",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST006434",
      "pubmed_id": "29912962"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11754bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114033028
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004329"
      ],
      "reported_trait_name": "Mean arterial pressure x alcohol consumption interaction (2df test) [EA]",
      "standard_trait_name": "alcohol drinking"
    },
    "association_info": {
      "ancestry": [
        "European=91110",
        "African American or Afro-Caribbean=21416",
        "Asian unspecified=12365",
        "Hispanic or Latin American=8470"
      ],
      "otg_id": "GCST006167_9",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST006167",
      "pubmed_id": "29912962"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114033028
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 21.73008330295326,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug METOPROLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (11029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114033028
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004329"
      ],
      "reported_trait_name": "Diastolic blood pressure x alcohol consumption interaction (2df test) [EA]",
      "standard_trait_name": "alcohol drinking"
    },
    "association_info": {
      "ancestry": [
        "European=91099",
        "African American or Afro-Caribbean=21416",
        "Asian unspecified=12365",
        "Hispanic or Latin American=8471"
      ],
      "otg_id": "GCST006166_8",
      "neg_log_pval": 22.096910013008056,
      "gwas_catalog_id": "GCST006166",
      "pubmed_id": "29912962"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114045297
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 14.522878745280337,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114045297
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 14.397940008672037,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 114045297
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 23.221848749616356,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000043591",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-1 adrenergic receptor agonist drug DOPAMINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000043591 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121334387
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121334387
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121334477
      },
      "alleles": {
        "reference": "G",
        "alternative": "GT"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 11.680685695909489,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143858bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121571953
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 43.678815972697684,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121572176
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 190.37059040089727,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121575416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 34.096910013008056,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121575416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005842"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "colorectal cancer"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 34.096910013008056,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121575416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 34.096910013008056,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121577821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=8556"
      ],
      "otg_id": "GCST000678",
      "neg_log_pval": 30.397940008672037,
      "gwas_catalog_id": "GCST000678",
      "pubmed_id": "20453838"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121577821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=2287"
      ],
      "otg_id": "GCST000365",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST000365",
      "pubmed_id": "19330030"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121577821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 169.69897000433602,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121577821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121577821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 163.22184874961636,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121579461
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer | illnesses of mother",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=330828"
      ],
      "otg_id": "NEALE2_20110_5",
      "neg_log_pval": 30.844827992822484,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121580797
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4741"
      ],
      "otg_id": "GCST002234",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST002234",
      "pubmed_id": "24143190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121580797
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4741"
      ],
      "otg_id": "GCST002234",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST002234",
      "pubmed_id": "24143190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121580917
      },
      "alleles": {
        "reference": "GC",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 321.65300282934044,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121584395
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer | illnesses of siblings",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=279478"
      ],
      "otg_id": "NEALE2_20111_5",
      "neg_log_pval": 14.096910013008056,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586602
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer in BRCA2 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=1703"
      ],
      "otg_id": "GCST000846",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST000846",
      "pubmed_id": "21060860"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586602
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 71.26440110030182,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=6346"
      ],
      "otg_id": "GCST000952",
      "neg_log_pval": 30.0,
      "gwas_catalog_id": "GCST000952",
      "pubmed_id": "21263130"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=8428"
      ],
      "otg_id": "GCST000811",
      "neg_log_pval": 12.698970004336019,
      "gwas_catalog_id": "GCST000811",
      "pubmed_id": "20872241"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121586676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=2287"
      ],
      "otg_id": "GCST000036",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST000036",
      "pubmed_id": "17529973"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121589148
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer (early onset)",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=6225"
      ],
      "otg_id": "GCST002346",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST002346",
      "pubmed_id": "24493630"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121589810
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 36.13804762507855,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121590702
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Cancer diagnosed by doctor",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=359981"
      ],
      "otg_id": "NEALE2_2453",
      "neg_log_pval": 13.229147988357855,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121591810
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer in BRCA2 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=8211"
      ],
      "otg_id": "GCST007302",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST007302",
      "pubmed_id": "23544012"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121592706
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Estrogen receptor status in HER2 negative breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=5452"
      ],
      "otg_id": "GCST003823",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST003823",
      "pubmed_id": "27764800"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121592803
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=754"
      ],
      "otg_id": "GCST000035",
      "neg_log_pval": 75.69897000433602,
      "gwas_catalog_id": "GCST000035",
      "pubmed_id": "17529967"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121592803
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121594355
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Estrogen receptor status in breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=8727"
      ],
      "otg_id": "GCST003821",
      "neg_log_pval": 11.221848749616356,
      "gwas_catalog_id": "GCST003821",
      "pubmed_id": "27764800"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "10",
        "position": 121598047
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 13.173925197299173,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000066468",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1852002
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 15.0,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1852002
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 15.0,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1855715
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 16.29810490633703,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (308214bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1865838
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [Japanese]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (298091bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1867384
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 26.22452645095722,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1867384
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 19.518557371497696,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1867384
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 19.619788758288394,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1877434
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180176",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (286496bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1877434
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 37.01300446027562,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (251679bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1880867
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (248245bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1887776
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 12.698970004336019,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1887776
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 1887776
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=754"
      ],
      "otg_id": "GCST000035",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST000035",
      "pubmed_id": "17529967"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17386857
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=407701"
      ],
      "otg_id": "SAIGE_250_2",
      "neg_log_pval": 9.896196279044043,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033"
      ],
      "otg_id": "GCST005047",
      "neg_log_pval": 10.494850021680094,
      "gwas_catalog_id": "GCST005047",
      "pubmed_id": "22885922"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033",
        "East Asian=18817",
        "South Asian=20019",
        "Hispanic or Latin American=2583"
      ],
      "otg_id": "GCST002352",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002352",
      "pubmed_id": "24509480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [EA]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894_2",
      "neg_log_pval": 13.096910013008056,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 21.30102999566398,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 16.397940008672037,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17387083
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [DGI+FUSION+WTCCC]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=4862"
      ],
      "otg_id": "GCST000025_2",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST000025",
      "pubmed_id": "17463249"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17388025
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007516",
      "neg_log_pval": 21.69897000433602,
      "gwas_catalog_id": "GCST007516",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17388025
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=2931"
      ],
      "otg_id": "GCST000028",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST000028",
      "pubmed_id": "17463246"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17388025
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [non-obese]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=4862"
      ],
      "otg_id": "GCST000277",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST000277",
      "pubmed_id": "19056611"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17388025
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [DGI+FUSION+WTCCC]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=2335"
      ],
      "otg_id": "GCST000024_2",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST000024",
      "pubmed_id": "17463248"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17388025
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 21.221848749616356,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 17390274
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007077",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST007077",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187486",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (943bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46684189
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Pulmonary embolism +/- dvt | non-cancer illness code, self-reported",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1093",
      "neg_log_pval": 13.853871964321762,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (34991bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739206
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism [Conditioned on rs1799963]",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=120158"
      ],
      "otg_id": "GCST004256_2",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST004256",
      "pubmed_id": "28373160"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739206
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism [Conditioned on rs1799963]",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=120158"
      ],
      "otg_id": "GCST004256_2",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST004256",
      "pubmed_id": "28373160"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Circulatory disease nec",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=404271"
      ],
      "otg_id": "SAIGE_459_9",
      "neg_log_pval": 12.829738284605043,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=120158"
      ],
      "otg_id": "GCST004256",
      "neg_log_pval": 12.301029995663981,
      "gwas_catalog_id": "GCST004256",
      "pubmed_id": "28373160"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Other disorders of circulatory system",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=404449"
      ],
      "otg_id": "SAIGE_459",
      "neg_log_pval": 12.882728704344236,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Other disorders of circulatory system",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=404449"
      ],
      "otg_id": "SAIGE_459",
      "neg_log_pval": 12.882728704344236,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0002140"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "Ischemic stroke"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug ARGATROBAN is Phase III for the indiciation HP_0002140 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003907"
      ],
      "reported_trait_name": "Blood clot in the leg (dvt) | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "deep vein thrombosis"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_5",
      "neg_log_pval": 19.56919957537582,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=60139"
      ],
      "otg_id": "GCST002808",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002808",
      "pubmed_id": "25772935"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=120158"
      ],
      "otg_id": "GCST004256",
      "neg_log_pval": 12.301029995663981,
      "gwas_catalog_id": "GCST004256",
      "pubmed_id": "28373160"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003907"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "deep vein thrombosis"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Circulatory disease nec",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=404271"
      ],
      "otg_id": "SAIGE_459_9",
      "neg_log_pval": 12.829738284605043,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Venous thromboembolism",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=60139"
      ],
      "otg_id": "GCST002808",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002808",
      "pubmed_id": "25772935"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003907"
      ],
      "reported_trait_name": "Deep venous thrombosis (dvt) | non-cancer illness code, self-reported",
      "standard_trait_name": "deep vein thrombosis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1094",
      "neg_log_pval": 20.081541349622885,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_7",
      "neg_log_pval": 12.362510270487489,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 46739505
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180210",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 61026176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003956"
      ],
      "reported_trait_name": "Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "seasonal allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_9",
      "neg_log_pval": 8.413929430513312,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183134",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "G protein-coupled receptor 44 antagonist drug SETIPIPRANT is Phase III for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 61026176
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003956"
      ],
      "reported_trait_name": "Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "seasonal allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_9",
      "neg_log_pval": 8.413929430513312,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183134",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "G protein-coupled receptor 44 antagonist drug QAV680 is Phase II for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62419070
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 26.0,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62419070
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 26.0,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62429955
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62429955
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62432345
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 62432345
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [CC16]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_2",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168539",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64566642
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=408393"
      ],
      "otg_id": "SAIGE_274_1",
      "neg_log_pval": 7.543633966870957,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64566642
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=408393"
      ],
      "otg_id": "SAIGE_274_1",
      "neg_log_pval": 7.543633966870957,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64566642
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=408393"
      ],
      "otg_id": "SAIGE_274_1",
      "neg_log_pval": 7.543633966870957,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168065",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64582330
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 15.066630665946775,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168065",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (9456bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64582330
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 15.066630665946775,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64582330
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 15.066630665946775,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug SULFINPYRAZONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64584591
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 23.07433525192862,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64584591
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 23.07433525192862,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64584591
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout | non-cancer illness code, self-reported",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1466",
      "neg_log_pval": 23.07433525192862,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168065",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (11717bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout [Japanese]",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2158"
      ],
      "otg_id": "GCST003925_2",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST003925",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168065",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Renal underexcretion gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1832"
      ],
      "otg_id": "GCST003926",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST003926",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Renal underexcretion gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1832"
      ],
      "otg_id": "GCST003926",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST003926",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168065",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout [Japanese]",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2158"
      ],
      "otg_id": "GCST003925_2",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST003925",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Renal underexcretion gout",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1832"
      ],
      "otg_id": "GCST003926",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST003926",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 64668434
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004274"
      ],
      "reported_trait_name": "Gout [Japanese]",
      "standard_trait_name": "gout"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2158"
      ],
      "otg_id": "GCST003925_2",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST003925",
      "pubmed_id": "27899376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197891",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 88962678
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168959",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 89011257
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 24.522878745280337,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168959",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 89014994
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression (broad)",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=322580"
      ],
      "otg_id": "GCST005902",
      "neg_log_pval": 10.171997842193115,
      "gwas_catalog_id": "GCST005902",
      "pubmed_id": "29662059"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000168959",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100711497
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (318127bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100722807
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [Japanese]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100722807
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 46.69897000433602,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug MEGESTROL ACETATE is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000082175 at this locus (306817bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100722807
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=69395"
      ],
      "otg_id": "GCST001238",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST001238",
      "pubmed_id": "21909115"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100722807
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 46.69897000433602,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100722807
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 8.14206473528057,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (306817bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100739815
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 39.096910013008056,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000082175 at this locus (289809bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100739815
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 9.55284196865778,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (289809bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100739815
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 20.34008379993015,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100739815
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 20.27490547891853,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100739815
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 38.813874644838485,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100753868
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (275756bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 100761177
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 10.168322150808534,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000082175",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (268448bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102846249
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=574"
      ],
      "otg_id": "GCST002665_5",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST002665",
      "pubmed_id": "25340798"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137745",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137745 at this locus (96747bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102846249
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=574"
      ],
      "otg_id": "GCST002665_5",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST002665",
      "pubmed_id": "25340798"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000118113",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000118113 at this locus (119199bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102846249
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=574"
      ],
      "otg_id": "GCST002665_5",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST002665",
      "pubmed_id": "25340798"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196611",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000196611 at this locus (48090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102846249
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=574"
      ],
      "otg_id": "GCST002665_5",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST002665",
      "pubmed_id": "25340798"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137673",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137673 at this locus (315500bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102850214
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease (severe)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=7100",
        "African American or Afro-Caribbean=2570"
      ],
      "otg_id": "GCST002350",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002350",
      "pubmed_id": "24621683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137673",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137673 at this locus (319465bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102850214
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease (severe)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=7100",
        "African American or Afro-Caribbean=2570"
      ],
      "otg_id": "GCST002350",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002350",
      "pubmed_id": "24621683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196611",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000196611 at this locus (52055bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102850214
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease (severe)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=7100",
        "African American or Afro-Caribbean=2570"
      ],
      "otg_id": "GCST002350",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002350",
      "pubmed_id": "24621683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137745",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137745 at this locus (92782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 102850214
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease (severe)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=7100",
        "African American or Afro-Caribbean=2570"
      ],
      "otg_id": "GCST002350",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002350",
      "pubmed_id": "24621683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000118113",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000118113 at this locus (123164bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 103082247
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196611",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196611 at this locus (284087bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 103082247
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000118113",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000118113 at this locus (355197bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 103082247
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137745",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000137745 at this locus (126515bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112956992
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worry",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=348219"
      ],
      "otg_id": "GCST006478",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006478",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug PALIPERIDONE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112956992
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worry",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=348219"
      ],
      "otg_id": "GCST006478",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006478",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug QUETIAPINE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112978997
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 8.487182241435127,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CLOZAPINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112978997
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 8.487182241435127,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug ILOPERIDONE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112978997
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004247"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "mood disorder"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 8.487182241435127,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 112978997
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004247"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "mood disorder"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 8.487182241435127,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113345201
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113345201
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor modulator drug CARIPRAZINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113345201
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug TRIMIPRAMINE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113493925
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worry",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=348219"
      ],
      "otg_id": "GCST006478",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006478",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113493925
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worry",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=348219"
      ],
      "otg_id": "GCST006478",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006478",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug BROMPERIDOL is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113500036
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 38.39794000867204,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (474846bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113500036
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 38.39794000867204,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113500036
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 38.39794000867204,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor modulator drug CARIPRAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113515625
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 12.761953896871205,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (459256bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113515625
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004247"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "mood disorder"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 12.761953896871205,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113515625
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 12.761953896871205,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug PERPHENAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113515625
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004247"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "mood disorder"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 12.761953896871205,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113515625
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 12.761953896871205,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113522272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003756"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "autism spectrum disorder"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003756 and targets the gene ENSG00000149295 at this locus (66031bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug ASENAPINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor partial agonist drug BIFEPRUNOX is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113541721
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000149295",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 113936459
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 114160077
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=9799"
      ],
      "otg_id": "GCST003227",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST003227",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 114160077
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24009"
      ],
      "otg_id": "GCST004348",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST004348",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118606652
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=5548"
      ],
      "otg_id": "GCST000439",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST000439",
      "pubmed_id": "19578367"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118606652
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST001058",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST001058",
      "pubmed_id": "21531791"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118609400
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=9799"
      ],
      "otg_id": "GCST003227",
      "neg_log_pval": 24.397940008672037,
      "gwas_catalog_id": "GCST003227",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118609400
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24009"
      ],
      "otg_id": "GCST004348",
      "neg_log_pval": 42.221848749616356,
      "gwas_catalog_id": "GCST004348",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118609400
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST003228",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST003228",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118609400
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=30659"
      ],
      "otg_id": "GCST004347",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST004347",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "11",
        "position": 118741072
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000540"
      ],
      "reported_trait_name": "Celiac disease or Rheumatoid arthritis",
      "standard_trait_name": "immune system disease"
    },
    "association_info": {
      "ancestry": [
        "European=38053"
      ],
      "otg_id": "GCST000987",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST000987",
      "pubmed_id": "21383967"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198851",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000198851 at this locus (424897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20008234
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 12.096910013008056,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug MILRINONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (361012bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20067099
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 13.096910013008056,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20067099
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 8.2839966563652,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20067099
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 13.537602002101044,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20207394
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (161851bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20424659
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0002140"
      ],
      "reported_trait_name": "Ischemic stroke",
      "standard_trait_name": "Ischemic stroke"
    },
    "association_info": {
      "ancestry": [
        "European=440328",
        "East Asian=45564",
        "South Asian=9144",
        "African American or Afro-Caribbean=20687",
        "Asian unspecified=555",
        "Hispanic or Latin American=1247"
      ],
      "otg_id": "GCST005843",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST005843",
      "pubmed_id": "29531354"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 20424659
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0002140"
      ],
      "reported_trait_name": "Ischemic stroke",
      "standard_trait_name": "Ischemic stroke"
    },
    "association_info": {
      "ancestry": [
        "European=440328",
        "East Asian=45564",
        "South Asian=9144",
        "African American or Afro-Caribbean=20687",
        "Asian unspecified=555",
        "Hispanic or Latin American=1247"
      ],
      "otg_id": "GCST005843",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST005843",
      "pubmed_id": "29531354"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 21170677
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0002140"
      ],
      "reported_trait_name": "Ischemic stroke (large artery atherosclerosis) [EA]",
      "standard_trait_name": "Ischemic stroke"
    },
    "association_info": {
      "ancestry": [
        "European=17565",
        "African American or Afro-Caribbean=375",
        "South Asian=4710"
      ],
      "otg_id": "GCST003322_2",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003322",
      "pubmed_id": "26732560"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172572",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (486296bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47792780
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.267891037697892,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47792780
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.267891037697892,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47802090
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003785"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "allergy"
    },
    "association_info": {
      "ancestry": [
        "European=360838"
      ],
      "otg_id": "GCST005038",
      "neg_log_pval": 10.941953769604718,
      "gwas_catalog_id": "GCST005038",
      "pubmed_id": "29083406"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase II for the indiciation EFO_0003785 and targets the gene ENSG00000111424 at this locus (39448bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47810716
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47810716
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000111424 at this locus (30821bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47810716
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47814585
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug PEFCALCITOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47814585
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug DOXERCALCIFEROL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47814585
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000111424 at this locus (26953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47814585
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CALCITRIOL is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47814585
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000111424 at this locus (26953bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47860570
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 12.517126416391246,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47860570
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 47860570
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 12.517126416391246,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48021974
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2062"
      ],
      "otg_id": "GCST007843",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST007843",
      "pubmed_id": "30891314"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000111424 at this locus (78926bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48025835
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48203270
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (260223bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48221500
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 9.53863955699212,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 48221500
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 9.53863955699212,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111424",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56001170
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56001170
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_2",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56001170
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56002984
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56002984
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000110944 at this locus (331190bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56002984
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56002984
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56002984
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug BRAZIKUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56344189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56344189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=12244"
      ],
      "otg_id": "GCST002738",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST002738",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56344189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=12244"
      ],
      "otg_id": "GCST002738",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST002738",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56344189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56346898
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56346898
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_8",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56346898
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56346898
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_8",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56347444
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 24.397940008672037,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56347444
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 24.397940008672037,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56350492
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56350492
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 56356420
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001494"
      ],
      "reported_trait_name": "Psoriasis vulgaris",
      "standard_trait_name": "psoriasis vulgaris"
    },
    "association_info": {
      "ancestry": [
        "European=8941"
      ],
      "otg_id": "GCST003268",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST003268",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000110944",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000110944 at this locus (16011bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 111395984
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_2",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000089022",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "MAP kinase-activated protein kinase 5 inhibitor drug GLPG-0259 is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000089022 at this locus (446244bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "12",
        "position": 111803962
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003829"
      ],
      "reported_trait_name": "Alcohol dependence",
      "standard_trait_name": "alcohol dependence"
    },
    "association_info": {
      "ancestry": [
        "East Asian=314"
      ],
      "otg_id": "GCST002293",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST002293",
      "pubmed_id": "24277619"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000111275",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Aldehyde dehydrogenase inhibitor drug DISULFIRAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000111275 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27902841
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "NR=7046",
        "European=7320",
        "NR, Hispanic or Latin American, African unspecified, Asian unspecified=636"
      ],
      "otg_id": "GCST002991",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST002991",
      "pubmed_id": "26098869"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27902841
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "NR=7046",
        "European=7320",
        "NR, Hispanic or Latin American, African unspecified, Asian unspecified=636"
      ],
      "otg_id": "GCST002991",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST002991",
      "pubmed_id": "26098869"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27919860
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=21536"
      ],
      "otg_id": "GCST005434",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST005434",
      "pubmed_id": "29422604"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27919860
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=21536"
      ],
      "otg_id": "GCST005434",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST005434",
      "pubmed_id": "29422604"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27919860
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=6785"
      ],
      "otg_id": "GCST002553",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002553",
      "pubmed_id": "25086665"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 27919860
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002618"
      ],
      "reported_trait_name": "Pancreatic cancer",
      "standard_trait_name": "pancreatic carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=6785"
      ],
      "otg_id": "GCST002553",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002553",
      "pubmed_id": "25086665"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122025",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 31671676
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000133105",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Relaxin receptor 2 activator drug SERELAXIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000133105 at this locus (67851bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 42378009
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003882"
      ],
      "reported_trait_name": "Osteoporosis | non-cancer illness code, self-reported",
      "standard_trait_name": "osteoporosis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1309",
      "neg_log_pval": 11.549904924128398,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000120659",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 11 inhibitor drug DENOSUMAB is Phase IV for the indiciation EFO_0003882 and targets the gene ENSG00000120659 at this locus (184727bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 112977466
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 11.096910013008056,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 112977466
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 11.085445301482366,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 112977466
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 11.096910013008056,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 112977466
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 11.085445301482366,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 113040195
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002506"
      ],
      "reported_trait_name": "Osteoarthritis",
      "standard_trait_name": "osteoarthritis"
    },
    "association_info": {
      "ancestry": [
        "European=8071"
      ],
      "otg_id": "GCST001209",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001209",
      "pubmed_id": "21871595"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000126218 at this locus (82619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 113218398
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 7.860750782428393,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug BETRIXABAN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 113218398
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 7.860750782428393,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "13",
        "position": 113218398
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 7.860750782428393,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000126218",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor X inhibitor drug IDRAPARINUX is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 22836440
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug CARFILZOMIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000100804 at this locus (180104bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 22836440
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258643",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000258643 at this locus (470396bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 22836440
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000129473",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000129473 at this locus (462350bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23116124
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood)",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1452",
        "European=2358",
        "Hispanic or Latin American=1313"
      ],
      "otg_id": "GCST001912",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST001912",
      "pubmed_id": "23512250"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (80894bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23119848
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood)",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=4735",
        "Hispanic or Latin American=10533",
        "African American or Afro-Caribbean=3972"
      ],
      "otg_id": "GCST005315",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST005315",
      "pubmed_id": "29348612"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23119848
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood) [ETV6-RUNX1 positive]",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=893"
      ],
      "otg_id": "GCST001320_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001320",
      "pubmed_id": "22076464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23119848
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000094"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (B-cell precursor)",
      "standard_trait_name": "B-cell acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=6381"
      ],
      "otg_id": "GCST002158",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST002158",
      "pubmed_id": "23996088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23119848
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood)",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=893"
      ],
      "otg_id": "GCST001320",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST001320",
      "pubmed_id": "22076464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 23119848
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000094"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia in childhood (B cell precursor)",
      "standard_trait_name": "B-cell acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=17051"
      ],
      "otg_id": "GCST005832",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST005832",
      "pubmed_id": "29632299"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 64219489
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=480359"
      ],
      "otg_id": "GCST005839",
      "neg_log_pval": 9.096910013008056,
      "gwas_catalog_id": "GCST005839",
      "pubmed_id": "29700475"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000140009",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 64227194
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7394"
      ],
      "otg_id": "GCST003148",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST003148",
      "pubmed_id": "26443449"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000140009",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor beta modulator drug ESTRAMUSTINE PHOSPHATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000140009 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "14",
        "position": 64230319
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 11.397940008672037,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000140009",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 27985172
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001059"
      ],
      "reported_trait_name": "Cataract",
      "standard_trait_name": "cataract"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_366",
      "neg_log_pval": 9.172630726946174,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000182256",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0001059 and targets the gene ENSG00000182256 at this locus (443188bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 51245609
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001512"
      ],
      "reported_trait_name": "Endometrial cancer",
      "standard_trait_name": "endometrial carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=11756"
      ],
      "otg_id": "GCST003524",
      "neg_log_pval": 12.301029995663981,
      "gwas_catalog_id": "GCST003524",
      "pubmed_id": "27135401"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137869",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 51261712
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001512"
      ],
      "reported_trait_name": "Endometrial cancer",
      "standard_trait_name": "endometrial carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=121885"
      ],
      "otg_id": "GCST006464",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST006464",
      "pubmed_id": "30093612"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137869",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 51261712
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001512"
      ],
      "reported_trait_name": "Endometrial cancer (endometrioid histology)",
      "standard_trait_name": "endometrial carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=54884"
      ],
      "otg_id": "GCST006465",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST006465",
      "pubmed_id": "30093612"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137869",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 63445726
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003144"
      ],
      "reported_trait_name": "Heart failure [EA]",
      "standard_trait_name": "heart failure"
    },
    "association_info": {
      "ancestry": [
        "European=20926",
        "African American or Afro-Caribbean=2895"
      ],
      "otg_id": "GCST000675_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST000675",
      "pubmed_id": "20445134"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000074410",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000074410 at this locus (63881bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 63696566
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458969"
      ],
      "otg_id": "GCST007656",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST007656",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000074410",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000074410 at this locus (314720bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73359833
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=59133"
      ],
      "otg_id": "GCST001499",
      "neg_log_pval": 16.522878745280337,
      "gwas_catalog_id": "GCST001499",
      "pubmed_id": "22544366"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73359833
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=59133"
      ],
      "otg_id": "GCST001499",
      "neg_log_pval": 16.522878745280337,
      "gwas_catalog_id": "GCST001499",
      "pubmed_id": "22544366"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73374914
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 35.32039042822024,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73374914
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 35.32039042822024,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73374914
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 26.69897000433602,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73374914
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 26.69897000433602,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73375705
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 14.522878745280337,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73375705
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 14.522878745280337,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73376665
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=118755"
      ],
      "otg_id": "GCST004297",
      "neg_log_pval": 11.096910013008056,
      "gwas_catalog_id": "GCST004297",
      "pubmed_id": "28416818"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73376665
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=118755"
      ],
      "otg_id": "GCST004297",
      "neg_log_pval": 11.096910013008056,
      "gwas_catalog_id": "GCST004297",
      "pubmed_id": "28416818"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73384923
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 27.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "15",
        "position": 73384923
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 27.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138622",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9806200
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9806200
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003756"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "autism spectrum disorder"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0003756 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9806200
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9852462
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9852462
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9852462
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9852462
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 9852462
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183454",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27337847
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27337847
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 11.676747899828312,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27337847
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000684"
      ],
      "reported_trait_name": "Respiratory diseases",
      "standard_trait_name": "respiratory system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007076",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST007076",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase II for the indiciation EFO_0000684 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27337847
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 12.204815410317575,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27338117
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 9.97061622231479,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27344528
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 8.866461091629782,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27358181
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 19.397940008672037,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27360103
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 12.795880017344075,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27360103
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 13.721246399047171,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 27360218
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0000964"
      ],
      "reported_trait_name": "Eczema",
      "standard_trait_name": "Eczema"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007075",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST007075",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000077238",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase IV for the indiciation HP_0000964 and targets the gene ENSG00000077238 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30159694
      },
      "alleles": {
        "reference": "GT",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 29.397940008672037,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (312964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30631546
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2252"
      ],
      "otg_id": "GCST000507",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST000507",
      "pubmed_id": "19838193"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000005844 at this locus (108362bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30792936
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 7.607581136972331,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (269751bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30931304
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "NR=4377"
      ],
      "otg_id": "GCST000834",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST000834",
      "pubmed_id": "20953189"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (408120bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30959620
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (436435bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 30989488
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (466304bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 31009757
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000005844",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (486572bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 31137821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 9.289274371510311,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000140675",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium/glucose cotransporter 2 inhibitor drug DAPAGLIFLOZIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000140675 at this locus (345181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 31137821
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000140675",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium/glucose cotransporter 2 inhibitor drug EMPAGLIFLOZIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000140675 at this locus (345181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56954132
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=22161"
      ],
      "otg_id": "GCST001003",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST001003",
      "pubmed_id": "21386085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56954132
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome (bivariate traits) [HDLC-WC]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=22161"
      ],
      "otg_id": "GCST001007_4",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST001007",
      "pubmed_id": "21386085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56956804
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001645"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "coronary heart disease"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 149.0,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087237",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cholesteryl ester transfer protein inhibitor drug ANACETRAPIB is Phase III for the indiciation EFO_0001645 and targets the gene ENSG00000087237 at this locus (5120bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56956804
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 149.0,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000070915 at this locus (40954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56956804
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003144"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "heart failure"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 149.0,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000070915 at this locus (40954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56956804
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [HDL]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=10564"
      ],
      "otg_id": "GCST001436_2",
      "neg_log_pval": 59.045757490560675,
      "gwas_catalog_id": "GCST001436",
      "pubmed_id": "22399527"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (40954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56959412
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome (bivariate traits) [BP-HDLC]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=22161"
      ],
      "otg_id": "GCST001007_2",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST001007",
      "pubmed_id": "21386085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56959412
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [HDL]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "South Asian=2554"
      ],
      "otg_id": "GCST000753_3",
      "neg_log_pval": 48.0,
      "gwas_catalog_id": "GCST000753",
      "pubmed_id": "20694148"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 56968820
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome (bivariate traits) [HDLC-GLUC]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=22161"
      ],
      "otg_id": "GCST001007_3",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST001007",
      "pubmed_id": "21386085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000070915",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (52971bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 71657426
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000102967",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dihydroorotate dehydrogenase inhibitor drug LEFLUNOMIDE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000102967 at this locus (351162bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89637957
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002506"
      ],
      "reported_trait_name": "Osteoarthritis",
      "standard_trait_name": "osteoarthritis"
    },
    "association_info": {
      "ancestry": [
        "European=455221"
      ],
      "otg_id": "GCST007093",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007093",
      "pubmed_id": "30664745"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0002506 and targets the gene ENSG00000258947 at this locus (283436bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89669749
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Malignant melanoma | cancer code, self-reported",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20001_1059",
      "neg_log_pval": 33.803837637410474,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89669749
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma [adjusted for rs4268748]",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=61457"
      ],
      "otg_id": "GCST003327_3",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST003327",
      "pubmed_id": "26829030"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89669749
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Malignant melanoma | cancer code, self-reported",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20001_1059",
      "neg_log_pval": 33.803837637410474,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89669749
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma [adjusted for rs4268748]",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=61457"
      ],
      "otg_id": "GCST003327_3",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST003327",
      "pubmed_id": "26829030"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=10422"
      ],
      "otg_id": "GCST001267",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST001267",
      "pubmed_id": "21983787"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=6122"
      ],
      "otg_id": "GCST002514",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002514",
      "pubmed_id": "24980573"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=5456"
      ],
      "otg_id": "GCST000437",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST000437",
      "pubmed_id": "19578364"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=5456"
      ],
      "otg_id": "GCST000437",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST000437",
      "pubmed_id": "19578364"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=10422"
      ],
      "otg_id": "GCST001267",
      "neg_log_pval": 26.522878745280337,
      "gwas_catalog_id": "GCST001267",
      "pubmed_id": "21983787"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89689495
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=6122"
      ],
      "otg_id": "GCST002514",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST002514",
      "pubmed_id": "24980573"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89780269
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Reported occurrences of cancer",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=58607"
      ],
      "otg_id": "NEALE2_40009",
      "neg_log_pval": 11.396639075651619,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89780269
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 44.69897000433602,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89780269
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Reported occurrences of cancer",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=58607"
      ],
      "otg_id": "NEALE2_40009",
      "neg_log_pval": 11.396639075651619,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89780269
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 44.69897000433602,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89780269
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Reported occurrences of cancer",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=58607"
      ],
      "otg_id": "NEALE2_40009",
      "neg_log_pval": 11.396639075651619,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89885119
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Malignant melanoma | cancer code, self-reported",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20001_1059",
      "neg_log_pval": 12.303643611266669,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89885119
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Malignant melanoma | cancer code, self-reported",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20001_1059",
      "neg_log_pval": 12.303643611266669,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002496"
      ],
      "reported_trait_name": "Actinic keratosis",
      "standard_trait_name": "actinic keratosis"
    },
    "association_info": {
      "ancestry": [
        "European=406033"
      ],
      "otg_id": "SAIGE_702_1",
      "neg_log_pval": 14.698970004336019,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0002496 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_11",
      "neg_log_pval": 28.661543506395397,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 36.39794000867204,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 36.39794000867204,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001927"
      ],
      "reported_trait_name": "Cutaneous squamous cell carcinoma",
      "standard_trait_name": "cutaneous squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=287137"
      ],
      "otg_id": "GCST003655",
      "neg_log_pval": 38.045757490560675,
      "gwas_catalog_id": "GCST003655",
      "pubmed_id": "27424798"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_1001927 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_11",
      "neg_log_pval": 28.661543506395397,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin, dx or hx",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_1",
      "neg_log_pval": 28.661543506395397,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89919709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin, dx or hx",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_1",
      "neg_log_pval": 28.661543506395397,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89924435
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_11",
      "neg_log_pval": 9.339134521996131,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89924435
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_11",
      "neg_log_pval": 9.339134521996131,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89924435
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin, dx or hx",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_1",
      "neg_log_pval": 9.339134521996131,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89924435
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Melanomas of skin, dx or hx",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=397762"
      ],
      "otg_id": "SAIGE_172_1",
      "neg_log_pval": 9.339134521996131,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89957798
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Cancer diagnosed by doctor",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=359981"
      ],
      "otg_id": "NEALE2_2453",
      "neg_log_pval": 12.515700160653214,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89957798
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Cancer diagnosed by doctor",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=359981"
      ],
      "otg_id": "NEALE2_2453",
      "neg_log_pval": 12.515700160653214,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89957798
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Cancer diagnosed by doctor",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=359981"
      ],
      "otg_id": "NEALE2_2453",
      "neg_log_pval": 12.515700160653214,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89960104
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=61457"
      ],
      "otg_id": "GCST003327",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST003327",
      "pubmed_id": "26829030"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89960104
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=61457"
      ],
      "otg_id": "GCST003327",
      "neg_log_pval": 43.69897000433602,
      "gwas_catalog_id": "GCST003327",
      "pubmed_id": "26829030"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89961218
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13550"
      ],
      "otg_id": "GCST003422",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003422",
      "pubmed_id": "26908436"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 89961218
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Squamous cell carcinoma",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13550"
      ],
      "otg_id": "GCST003422",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003422",
      "pubmed_id": "26908436"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 90000528
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 21.221848749616356,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 90000528
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=5456"
      ],
      "otg_id": "GCST000437",
      "neg_log_pval": 21.221848749616356,
      "gwas_catalog_id": "GCST000437",
      "pubmed_id": "19578364"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 90000528
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 21.221848749616356,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "16",
        "position": 90000528
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=5456"
      ],
      "otg_id": "GCST000437",
      "neg_log_pval": 21.221848749616356,
      "gwas_catalog_id": "GCST000437",
      "pubmed_id": "19578364"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000258947",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4044350
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4044350
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4049808
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4049808
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4049808
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4049808
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4077199
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.644381843915278,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000196689 at this locus (467788bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4082570
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 4082570
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196689",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 7559652
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004194"
      ],
      "reported_trait_name": "IgA nephropathy",
      "standard_trait_name": "IGA glomerulonephritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5704"
      ],
      "otg_id": "GCST001364",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST001364",
      "pubmed_id": "22197929"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000161955",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 7587859
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004194"
      ],
      "reported_trait_name": "IgA nephropathy",
      "standard_trait_name": "IGA glomerulonephritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5704"
      ],
      "otg_id": "GCST001364",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST001364",
      "pubmed_id": "22197929"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000161955",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (26251bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 34243528
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 20.30102999566398,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000172156",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Eotaxin inhibitor drug BERTILIMUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000172156 at this locus (42141bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 39895095
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001061"
      ],
      "reported_trait_name": "Cervical cancer [Matched]",
      "standard_trait_name": "cervical carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4392"
      ],
      "otg_id": "GCST002082",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST002082",
      "pubmed_id": "23817570"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000131747",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA topoisomerase II alpha inhibitor drug DOXORUBICIN is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000131747 at this locus (493430bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 39895095
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001061"
      ],
      "reported_trait_name": "Cervical cancer [Matched]",
      "standard_trait_name": "cervical carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4392"
      ],
      "otg_id": "GCST002082",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST002082",
      "pubmed_id": "23817570"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000141736",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Receptor protein-tyrosine kinase erbB-2 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000141736 at this locus (164669bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 39909987
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood)",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=4735",
        "Hispanic or Latin American=10533",
        "African American or Afro-Caribbean=3972"
      ],
      "otg_id": "GCST005315",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST005315",
      "pubmed_id": "29348612"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000131747",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA topoisomerase II alpha inhibitor drug ETOPOSIDE PHOSPHATE is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 39909987
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000220"
      ],
      "reported_trait_name": "Acute lymphoblastic leukemia (childhood)",
      "standard_trait_name": "acute lymphoblastic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=4735",
        "Hispanic or Latin American=10533",
        "African American or Afro-Caribbean=3972"
      ],
      "otg_id": "GCST005315",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST005315",
      "pubmed_id": "29348612"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000131747",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA topoisomerase II alpha inhibitor drug DAUNORUBICIN is Phase IV for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 43715814
      },
      "alleles": {
        "reference": "CT",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003931"
      ],
      "reported_trait_name": "Fractured/broken bones in last 5 years",
      "standard_trait_name": "bone fracture"
    },
    "association_info": {
      "ancestry": [
        "European=359241"
      ],
      "otg_id": "NEALE2_2463",
      "neg_log_pval": 12.11747546204512,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167941",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (37925bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 43721487
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003931"
      ],
      "reported_trait_name": "Fractures",
      "standard_trait_name": "bone fracture"
    },
    "association_info": {
      "ancestry": [
        "European=426795"
      ],
      "otg_id": "GCST006980",
      "neg_log_pval": 40.30102999566398,
      "gwas_catalog_id": "GCST006980",
      "pubmed_id": "30598549"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167941",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (32252bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 43749471
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003931"
      ],
      "reported_trait_name": "Fractures",
      "standard_trait_name": "bone fracture"
    },
    "association_info": {
      "ancestry": [
        "East Asian=800",
        "European=264173"
      ],
      "otg_id": "GCST006423",
      "neg_log_pval": 24.522878745280337,
      "gwas_catalog_id": "GCST006423",
      "pubmed_id": "30158200"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167941",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (4268bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 45486856
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Remission after SSRI treatment in MDD or neuroticism",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=171776"
      ],
      "otg_id": "GCST005835",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST005835",
      "pubmed_id": "29559929"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000120088",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (297425bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 45779273
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 21.624885315307775,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000120088",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (5007bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 59739396
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 15.265200170411154,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167434",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Carbonic anhydrase IV inhibitor drug TOPIRAMATE is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000167434 at this locus (410546bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63471557
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 24.154901959985743,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug FOSINOPRIL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000159640 at this locus (5504bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63471557
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 24.154901959985743,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000007314 at this locus (466997bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63471587
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 19.50811606596098,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug CAPTOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63471587
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 19.50811606596098,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63471587
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 19.50811606596098,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug BUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (466967bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 10.26440110030182,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 10.26440110030182,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 10.26440110030182,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 10.172630726946174,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 10.172630726946174,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63478937
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 10.172630726946174,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63610240
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63610240
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000159640",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Angiotensin-converting enzyme inhibitor drug PERINDOPRIL is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 63610240
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000007314 at this locus (328315bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 64309731
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (336814bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 64324605
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 10.20210951694165,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000007314",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (351688bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 70341044
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000123700",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (160996bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 70351197
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000123700",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "17",
        "position": 70351197
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000123700",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 12797695
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-positive)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=9299",
        "European=45790"
      ],
      "otg_id": "GCST006048",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST006048",
      "pubmed_id": "24532676"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000176014",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 12797695
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=20965"
      ],
      "otg_id": "GCST001454",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001454",
      "pubmed_id": "22446963"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000176014",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 12821594
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Esophageal cancer (squamous cell)",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4075"
      ],
      "otg_id": "GCST001674",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST001674",
      "pubmed_id": "22960999"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000176014",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 12821594
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000707"
      ],
      "reported_trait_name": "Esophageal cancer (squamous cell)",
      "standard_trait_name": "squamous cell carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4075"
      ],
      "otg_id": "GCST001674",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST001674",
      "pubmed_id": "22960999"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000176014",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 12821594
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002916"
      ],
      "reported_trait_name": "Esophageal cancer (squamous cell)",
      "standard_trait_name": "esophageal carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4075"
      ],
      "otg_id": "GCST001674",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST001674",
      "pubmed_id": "22960999"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000176014",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0002916 and targets the gene ENSG00000176014 at this locus (477275bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60144750
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity (early onset extreme)",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=2258"
      ],
      "otg_id": "GCST000663",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST000663",
      "pubmed_id": "20421936"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (226313bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60183189
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Obesity class I]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_4",
      "neg_log_pval": 35.69897000433602,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187873bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60183864
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [children]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=2796"
      ],
      "otg_id": "GCST000317_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST000317",
      "pubmed_id": "19151714"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60183864
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=2796"
      ],
      "otg_id": "GCST000317",
      "neg_log_pval": 14.301029995663981,
      "gwas_catalog_id": "GCST000317",
      "pubmed_id": "19151714"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60183864
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [adults]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=2796"
      ],
      "otg_id": "GCST000317_2",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST000317",
      "pubmed_id": "19151714"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60184530
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Overweight]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_5",
      "neg_log_pval": 26.69897000433602,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (186533bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60185354
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=408792"
      ],
      "otg_id": "SAIGE_278_1",
      "neg_log_pval": 11.251037138743838,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60185354
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity (early onset extreme)",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=6889"
      ],
      "otg_id": "GCST001957",
      "neg_log_pval": 13.045757490560675,
      "gwas_catalog_id": "GCST001957",
      "pubmed_id": "23563609"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60185354
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Overweight, obesity and other hyperalimentation",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_278",
      "neg_log_pval": 11.126098402135538,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 60185715
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Obesity class II]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_3",
      "neg_log_pval": 21.522878745280337,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000166603",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185347bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63115978
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000096"
      ],
      "reported_trait_name": "Follicular lymphoma",
      "standard_trait_name": "neoplasm of mature B-cells"
    },
    "association_info": {
      "ancestry": [
        "European=10486"
      ],
      "otg_id": "GCST002643",
      "neg_log_pval": 9.096910013008056,
      "gwas_catalog_id": "GCST002643",
      "pubmed_id": "25279986"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase II for the indiciation EFO_0000096 and targets the gene ENSG00000171791 at this locus (7369bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63121512
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=17691"
      ],
      "otg_id": "GCST004146",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST004146",
      "pubmed_id": "28165464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63121512
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=17691"
      ],
      "otg_id": "GCST004146",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST004146",
      "pubmed_id": "28165464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126261
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=10767"
      ],
      "otg_id": "GCST003468",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST003468",
      "pubmed_id": "26956414"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126261
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=10767"
      ],
      "otg_id": "GCST003468",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST003468",
      "pubmed_id": "26956414"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126316
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=8400"
      ],
      "otg_id": "GCST002073",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST002073",
      "pubmed_id": "23770605"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126316
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=8400"
      ],
      "otg_id": "GCST002073",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST002073",
      "pubmed_id": "23770605"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126688
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=8400"
      ],
      "otg_id": "GCST002073",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST002073",
      "pubmed_id": "23770605"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63126688
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=8400"
      ],
      "otg_id": "GCST002073",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST002073",
      "pubmed_id": "23770605"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63293960
      },
      "alleles": {
        "reference": "C",
        "alternative": "CT"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "18",
        "position": 63293960
      },
      "alleles": {
        "reference": "CT",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 1031439
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Advanced age-related macular degeneration [EA]",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=33976"
      ],
      "otg_id": "GCST003219_2",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003219",
      "pubmed_id": "26691988"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197766",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Complement factor D inhibitor drug LAMPALIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000197766 at this locus (167810bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 4069121
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=17691"
      ],
      "otg_id": "GCST004146",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST004146",
      "pubmed_id": "28165464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167658",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Elongation factor 2 inhibitor drug DENILEUKIN DIFTITOX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000167658 at this locus (83658bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 7634461
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0006859"
      ],
      "reported_trait_name": "Neuropathic pain in head and neck cancer",
      "standard_trait_name": "head and neck malignant neoplasia"
    },
    "association_info": {
      "ancestry": [
        "European=1043"
      ],
      "otg_id": "GCST005934",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST005934",
      "pubmed_id": "29884837"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171105",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Insulin receptor inhibitor drug LINSITINIB is Phase II for the indiciation EFO_0006859 and targets the gene ENSG00000171105 at this locus (340047bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10317045
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 21.69897000433602,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (169080bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10352442
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10352442
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 11.517984423549288,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10352442
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 13.045757490560675,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10359299
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (126826bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10362257
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (123868bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10467167
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (18959bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10631494
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 9.019088062223156,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase IV for the indiciation EFO_0003885 and targets the gene ENSG00000079999 at this locus (127936bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10631494
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 9.019088062223156,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180739",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sphingosine 1-phosphate receptor Edg-8 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000180739 at this locus (113564bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10707416
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 9.378437388797577,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (203859bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 10775530
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000079999",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (271972bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11052925
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction (early onset)",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=6042"
      ],
      "otg_id": "GCST000340",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST000340",
      "pubmed_id": "19198609"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11052925
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Coronary artery disease or ischemic stroke",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "NR=123388"
      ],
      "otg_id": "GCST002287",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST002287",
      "pubmed_id": "24262325"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (324283bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11052925
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction (early onset)",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=6042"
      ],
      "otg_id": "GCST000340",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST000340",
      "pubmed_id": "19198609"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11064259
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Stroke",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=446696",
        "East Asian=45564",
        "South Asian=9144",
        "African American or Afro-Caribbean=20695",
        "Asian unspecified=698",
        "Hispanic or Latin American=1557"
      ],
      "otg_id": "GCST005838",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST005838",
      "pubmed_id": "29531354"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (312949bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077477
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077477
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077488
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 8.777283528852417,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077488
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 8.777283528852417,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077571
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 35.71175077442801,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077571
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 12.602059991327963,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11077571
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11091630
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 40.30102999566398,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11091630
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 21.096910013008056,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11091630
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 23.4089353929735,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11113589
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 7.705313375720557,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (263618bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11192878
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (184329bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11313027
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=87827"
      ],
      "otg_id": "GCST005077",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST005077",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000187266 at this locus (64180bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 11386305
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 8.2518119729938,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000187266",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (1963bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 40847202
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000571"
      ],
      "reported_trait_name": "Lung adenocarcinoma",
      "standard_trait_name": "lung adenocarcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=66756"
      ],
      "otg_id": "GCST004744",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST004744",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000167601",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase receptor UFO inhibitor drug R428 is Phase II for the indiciation EFO_0000571 and targets the gene ENSG00000167601 at this locus (372022bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "19",
        "position": 42196795
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000105409",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium/potassium-transporting ATPase inhibitor drug DIGOXIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000105409 at this locus (199298bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 9977740
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115758",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (462229bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 10570604
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer [EA]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115758",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 10570604
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 16.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115758",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 10570604
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=67543",
        "Sub-Saharan African, African American or Afro-Caribbean=10463",
        "East Asian=6954",
        "Hispanic or Latin American=2080"
      ],
      "otg_id": "GCST002606",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002606",
      "pubmed_id": "25217961"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115758",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 25390277
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=241704"
      ],
      "otg_id": "GCST004483",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST004483",
      "pubmed_id": "27363682"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000119772",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (47687bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 25406569
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=14421"
      ],
      "otg_id": "GCST004099",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST004099",
      "pubmed_id": "28112199"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000119772",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (63979bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 25406569
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy)",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=14421"
      ],
      "otg_id": "GCST004099",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST004099",
      "pubmed_id": "28112199"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000119772",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000119772 at this locus (63979bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 26691496
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 35.59516628338006,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171303",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 26691496
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 39.522019692388156,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171303",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 26697157
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [Japanese]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707_2",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171303",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 26700700
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 35.37263414340727,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171303",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 26707543
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 17.69897000433602,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171303",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 31580756
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=17500"
      ],
      "otg_id": "GCST003983",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST003983",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000277893",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 31956355
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=43590"
      ],
      "otg_id": "GCST005116",
      "neg_log_pval": 25.69897000433602,
      "gwas_catalog_id": "GCST005116",
      "pubmed_id": "29146897"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000277893",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (375418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1639"
      ],
      "otg_id": "GCST000914",
      "neg_log_pval": 20.096910013008056,
      "gwas_catalog_id": "GCST000914",
      "pubmed_id": "21151128"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000170820",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1639"
      ],
      "otg_id": "GCST000914",
      "neg_log_pval": 20.096910013008056,
      "gwas_catalog_id": "GCST000914",
      "pubmed_id": "21151128"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48751020
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1639"
      ],
      "otg_id": "GCST000914",
      "neg_log_pval": 20.096910013008056,
      "gwas_catalog_id": "GCST000914",
      "pubmed_id": "21151128"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000170820",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48974473
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug LH (MENOTROPINS) is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48974473
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138039",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 48974473
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000660"
      ],
      "reported_trait_name": "Polycystic ovary syndrome",
      "standard_trait_name": "polycystic ovary syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5255"
      ],
      "otg_id": "GCST001634",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST001634",
      "pubmed_id": "22885925"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000170820",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Follicle stimulating hormone receptor agonist drug HUMAN FSH is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 112851991
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0007427"
      ],
      "reported_trait_name": "Pericarditis",
      "standard_trait_name": "pericarditis"
    },
    "association_info": {
      "ancestry": [
        "European=407052"
      ],
      "otg_id": "SAIGE_420_2",
      "neg_log_pval": 7.52432881167557,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000125538",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-1 beta inhibitor drug RILONACEPT is Phase III for the indiciation EFO_0007427 and targets the gene ENSG00000125538 at this locus (15088bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 156156523
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115159",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000115159 at this locus (278767bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 156254801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 17.522878745280337,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115159",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 156254801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=480359"
      ],
      "otg_id": "GCST005839",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005839",
      "pubmed_id": "29700475"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115159",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 156300636
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depressed affect",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=357957"
      ],
      "otg_id": "GCST006475",
      "neg_log_pval": 7.4889191544608815,
      "gwas_catalog_id": "GCST006475",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115159",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (134654bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 161624943
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.54284051026846,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (367302bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 161726994
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 7.732828271596986,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 161726994
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 7.580044251510242,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 161989345
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug LINAGLIPTIN is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000197635 at this locus (2901bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162254026
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162254026
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162254026
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 17.418639958543828,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162254026
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 17.418639958543828,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 7.709543459425466,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=19102"
      ],
      "otg_id": "GCST001191",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST001191",
      "pubmed_id": "21829393"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=5000"
      ],
      "otg_id": "GCST000038",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST000038",
      "pubmed_id": "17554260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=5000"
      ],
      "otg_id": "GCST000038",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST000038",
      "pubmed_id": "17554260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162267541
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=19102"
      ],
      "otg_id": "GCST001191",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST001191",
      "pubmed_id": "21829393"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162272314
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA, conditional on rs1990760]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_5",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162272314
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [conditional on rs1990760]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_9",
      "neg_log_pval": 18.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162311236
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (237021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162404181
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=12244"
      ],
      "otg_id": "GCST002738",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST002738",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 162404181
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000197635",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 181443625
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 10.012333735073724,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000115232",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Integrin alpha-4/beta-1 inhibitor drug NATALIZUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000115232 at this locus (13578bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 212432139
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4325"
      ],
      "otg_id": "GCST001457",
      "neg_log_pval": 13.045757490560675,
      "gwas_catalog_id": "GCST001457",
      "pubmed_id": "22452962"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000178568",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Receptor protein-tyrosine kinase erbB-4 inhibitor drug BMS-690514 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000178568 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217802649
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458969"
      ],
      "otg_id": "GCST007656",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007656",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163464",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (360196bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217802649
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458969"
      ],
      "otg_id": "GCST007656",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007656",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (322641bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217818431
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163464",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (344415bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217818431
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug DANIRIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (306858bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217858732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 9.466355021201236,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163464",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor A modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000163464 at this locus (304113bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 217858732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 9.466355021201236,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000180871 at this locus (266557bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 218145423
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 8.682610761959468,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 218145423
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 218145423
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=26405"
      ],
      "otg_id": "GCST000964",
      "neg_log_pval": 8.056505484093897,
      "gwas_catalog_id": "GCST000964",
      "pubmed_id": "21297633"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 218145423
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000180871",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000180871 at this locus (8173bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 218145423
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163464",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000163464 at this locus (17422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 241355498
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=17691"
      ],
      "otg_id": "GCST004146",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004146",
      "pubmed_id": "28165464"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000188389",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Programmed cell death protein 1 inhibitor drug NIVOLUMAB is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000188389 at this locus (494386bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 241443449
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000188389",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "2",
        "position": 241443449
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000188389",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1629905
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1629905
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16559"
      ],
      "otg_id": "GCST000392",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST000392",
      "pubmed_id": "19430480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1635560
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 9.526299949462304,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1635560
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 9.526299949462304,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1701391
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 54.01739783478714,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1701391
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 41.87573133737034,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000088832 at this locus (308219bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 1701391
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 54.01739783478714,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000088832",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 45600808
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.4634655452861525,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (408100bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46006273
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 10.576918041702768,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (2636bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46065258
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.402641632544848,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (48698bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46105671
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-positive)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=43327"
      ],
      "otg_id": "GCST005568",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST005568",
      "pubmed_id": "23143596"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (89110bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46111557
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 11.569280112136719,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (94996bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46118343
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 11.397940008672037,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000100985 at this locus (101782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46118343
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 11.397940008672037,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (101782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46118343
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-positive)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=9299",
        "European=45790"
      ],
      "otg_id": "GCST006048",
      "neg_log_pval": 12.698970004336019,
      "gwas_catalog_id": "GCST006048",
      "pubmed_id": "24532676"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (101782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46119308
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=25708"
      ],
      "otg_id": "GCST000679",
      "neg_log_pval": 8.244874758392445,
      "gwas_catalog_id": "GCST000679",
      "pubmed_id": "20453842"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46119308
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=15853"
      ],
      "otg_id": "GCST000232",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST000232",
      "pubmed_id": "18794853"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46119308
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-positive)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=43327"
      ],
      "otg_id": "GCST005568",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST005568",
      "pubmed_id": "23143596"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46120612
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46120612
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46120612
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959_3",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46120612
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_2",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46246518
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.61253898367965,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (229958bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 46407574
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.818633826857316,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100985",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (391013bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 58792844
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 8.34338536184194,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug TRASTUZUMAB EMTANSINE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 58792844
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 8.34338536184194,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 58900136
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005842"
      ],
      "reported_trait_name": "Colorectal cancer",
      "standard_trait_name": "colorectal cancer"
    },
    "association_info": {
      "ancestry": [
        "East Asian=70506"
      ],
      "otg_id": "GCST007552",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007552",
      "pubmed_id": "30529582"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000101162 at this locus (119118bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59084069
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.5130894413060085,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59084069
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.5130894413060085,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59138970
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 9.099086932262331,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000101162 at this locus (112317bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59249254
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 11.397940008672037,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000101162 at this locus (222600bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59396049
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.339507340775082,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 59396049
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=89677"
      ],
      "otg_id": "GCST007236",
      "neg_log_pval": 7.339507340775082,
      "gwas_catalog_id": "GCST007236",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101162",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 63731211
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 17.522878745280337,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101213",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "20",
        "position": 63731211
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22548"
      ],
      "otg_id": "GCST001942",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST001942",
      "pubmed_id": "23535732"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000101213",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "21",
        "position": 33391982
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_2",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142166",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interferon-alpha/beta receptor alpha chain antagonist drug ANIFROLUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000142166 at this locus (32118bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 24262890
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000128271",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 24262890
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease [additive model]",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000128271",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 24266203
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000128271",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (151677bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 24276750
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 8.428291168191313,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000128271",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (141129bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 36862461
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 7.7544873321858505,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100385",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100385 at this locus (263382bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 37191071
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=29652"
      ],
      "otg_id": "GCST005536",
      "neg_log_pval": 7.748198311221298,
      "gwas_catalog_id": "GCST005536",
      "pubmed_id": "25751624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100385",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (16018bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "22",
        "position": 37195278
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=8207"
      ],
      "otg_id": "GCST000258",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST000258",
      "pubmed_id": "18978792"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000100385",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (20224bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 2943458
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Body mass index (change over time) in chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "NR=237"
      ],
      "otg_id": "GCST004105",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST004105",
      "pubmed_id": "28044437"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091181",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 receptor subunit alpha inhibitor drug BENRALIZUMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000091181 at this locus (122868bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 11467491
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196639",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Histamine H1 receptor agonist drug TOLAZOLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196639 at this locus (203935bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 11549277
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196639",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Histamine H1 receptor antagonist drug HYDROXYZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 11549277
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196639",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Histamine H1 receptor agonist drug BETAHISTINE is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 11549277
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196639",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Histamine H1 receptor antagonist drug DIBENZEPIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12288284
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007077",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007077",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12288284
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Diabetes diagnosed by doctor",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=360192"
      ],
      "otg_id": "NEALE2_2443",
      "neg_log_pval": 7.5486127463375,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug PIOGLITAZONE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12288284
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007077",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007077",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12288284
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007077",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007077",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12288284
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Diabetes diagnosed by doctor",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=360192"
      ],
      "otg_id": "NEALE2_2443",
      "neg_log_pval": 7.5486127463375,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12350773
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033"
      ],
      "otg_id": "GCST005047",
      "neg_log_pval": 8.795880017344075,
      "gwas_catalog_id": "GCST005047",
      "pubmed_id": "22885922"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12350773
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033"
      ],
      "otg_id": "GCST005047",
      "neg_log_pval": 8.795880017344075,
      "gwas_catalog_id": "GCST005047",
      "pubmed_id": "22885922"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12350773
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033"
      ],
      "otg_id": "GCST005047",
      "neg_log_pval": 8.795880017344075,
      "gwas_catalog_id": "GCST005047",
      "pubmed_id": "22885922"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [EA]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894_2",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007516",
      "neg_log_pval": 18.522878745280337,
      "gwas_catalog_id": "GCST007516",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033",
        "East Asian=18817",
        "South Asian=20019",
        "Hispanic or Latin American=2583"
      ],
      "otg_id": "GCST002352",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST002352",
      "pubmed_id": "24509480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [EA]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894_2",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007516",
      "neg_log_pval": 18.522878745280337,
      "gwas_catalog_id": "GCST007516",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033",
        "East Asian=18817",
        "South Asian=20019",
        "Hispanic or Latin American=2583"
      ],
      "otg_id": "GCST002352",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST002352",
      "pubmed_id": "24509480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=69033",
        "East Asian=18817",
        "South Asian=20019",
        "Hispanic or Latin American=2583"
      ],
      "otg_id": "GCST002352",
      "neg_log_pval": 9.221848749616356,
      "gwas_catalog_id": "GCST002352",
      "pubmed_id": "24509480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 17.0,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007516",
      "neg_log_pval": 18.522878745280337,
      "gwas_catalog_id": "GCST007516",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 17.0,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes [EA]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "South Asian=13532",
        "European=20298",
        "NR=149821"
      ],
      "otg_id": "GCST004894_2",
      "neg_log_pval": 13.698970004336019,
      "gwas_catalog_id": "GCST004894",
      "pubmed_id": "28869590"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes (adjusted for BMI)",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007518",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST007518",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12351626
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 17.0,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12353341
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 23.69897000433602,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12353341
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 23.69897000433602,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12353341
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 23.69897000433602,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12355414
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=70127"
      ],
      "otg_id": "GCST005413",
      "neg_log_pval": 15.357832365595055,
      "gwas_catalog_id": "GCST005413",
      "pubmed_id": "29358691"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12355414
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=70127"
      ],
      "otg_id": "GCST005413",
      "neg_log_pval": 15.357832365595055,
      "gwas_catalog_id": "GCST005413",
      "pubmed_id": "29358691"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 12355414
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=70127"
      ],
      "otg_id": "GCST005413",
      "neg_log_pval": 15.357832365595055,
      "gwas_catalog_id": "GCST005413",
      "pubmed_id": "29358691"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000132170",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38592651
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38592651
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38592651
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 15.12010167566999,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 15.12010167566999,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 13.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 13.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 13.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38668824
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 15.12010167566999,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38725184
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 7.87942606879415,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38725184
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 7.87942606879415,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38725184
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation and flutter",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=395739"
      ],
      "otg_id": "SAIGE_427_2",
      "neg_log_pval": 7.87942606879415,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 14.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 19.619607839942972,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 19.619607839942972,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 14.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 14.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 19.619607839942972,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 38730434
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000183873",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46150778
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001060"
      ],
      "reported_trait_name": "Malabsorption/coeliac disease | non-cancer illness code, self-reported",
      "standard_trait_name": "celiac disease"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1456",
      "neg_log_pval": 10.553695886048077,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (247604bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46164194
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001060"
      ],
      "reported_trait_name": "Celiac disease [conditioned on rs2097282]",
      "standard_trait_name": "celiac disease"
    },
    "association_info": {
      "ancestry": [
        "European=23649",
        "South Asian=620"
      ],
      "otg_id": "GCST005523_7",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST005523",
      "pubmed_id": "22057235"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (261019bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46193709
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001060"
      ],
      "reported_trait_name": "Celiac disease",
      "standard_trait_name": "celiac disease"
    },
    "association_info": {
      "ancestry": [
        "European=15283"
      ],
      "otg_id": "GCST000612",
      "neg_log_pval": 10.597222930389652,
      "gwas_catalog_id": "GCST000612",
      "pubmed_id": "20190752"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (290535bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46240253
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001060"
      ],
      "reported_trait_name": "Celiac disease",
      "standard_trait_name": "celiac disease"
    },
    "association_info": {
      "ancestry": [
        "European=4634"
      ],
      "otg_id": "GCST002520",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST002520",
      "pubmed_id": "24999842"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (337078bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46336534
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001060"
      ],
      "reported_trait_name": "Celiac disease",
      "standard_trait_name": "celiac disease"
    },
    "association_info": {
      "ancestry": [
        "European=23649",
        "South Asian=620"
      ],
      "otg_id": "GCST005523",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST005523",
      "pubmed_id": "22057235"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (433359bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46387167
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004268"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "sclerosing cholangitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121807",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000121807 at this locus (26239bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46387167
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004268"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "sclerosing cholangitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000160791 at this locus (10962bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46387167
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000173585 at this locus (483992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46387167
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000173585",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000173585 at this locus (483992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46410189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000180"
      ],
      "reported_trait_name": "Setpoint viral load in HIV-1 infection",
      "standard_trait_name": "HIV-1 infection"
    },
    "association_info": {
      "ancestry": [
        "European=6315"
      ],
      "otg_id": "GCST003183",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST003183",
      "pubmed_id": "26553974"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121807",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000121807 at this locus (49262bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46410189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000180"
      ],
      "reported_trait_name": "Setpoint viral load in HIV-1 infection",
      "standard_trait_name": "HIV-1 infection"
    },
    "association_info": {
      "ancestry": [
        "European=6315"
      ],
      "otg_id": "GCST003183",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST003183",
      "pubmed_id": "26553974"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 46410189
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000180"
      ],
      "reported_trait_name": "Setpoint viral load in HIV-1 infection",
      "standard_trait_name": "HIV-1 infection"
    },
    "association_info": {
      "ancestry": [
        "European=6315"
      ],
      "otg_id": "GCST003183",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST003183",
      "pubmed_id": "26553974"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000160791",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "C-C chemokine receptor type 5 antagonist drug MARAVIROC is Phase IV for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52234850
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (220268bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52253452
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (201667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52422957
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002506"
      ],
      "reported_trait_name": "Osteoarthritis; localized",
      "standard_trait_name": "osteoarthritis"
    },
    "association_info": {
      "ancestry": [
        "European=398213"
      ],
      "otg_id": "SAIGE_740_1",
      "neg_log_pval": 7.847711655616943,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000239732",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (196795bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52594040
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 12.698970004336019,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52594040
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 12.301029995663981,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52687289
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002506"
      ],
      "reported_trait_name": "Osteoarthritis",
      "standard_trait_name": "osteoarthritis"
    },
    "association_info": {
      "ancestry": [
        "European=18419"
      ],
      "otg_id": "GCST001592",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001592",
      "pubmed_id": "22763110"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000239732",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (461126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52694788
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004616"
      ],
      "reported_trait_name": "Osteoarthritis of the hip or knee",
      "standard_trait_name": "osteoarthritis, knee"
    },
    "association_info": {
      "ancestry": [
        "European=417596"
      ],
      "otg_id": "GCST007092",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007092",
      "pubmed_id": "30664745"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000239732",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase II for the indiciation EFO_0004616 and targets the gene ENSG00000239732 at this locus (468625bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52781889
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia, schizoaffective disorder or bipolar disorder",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "NR, African American or Afro-Caribbean, European, African unspecified, Asian unspecified, Other=48070"
      ],
      "otg_id": "GCST002254",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002254",
      "pubmed_id": "24166486"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (288821bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52799203
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=61220"
      ],
      "otg_id": "GCST001877",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST001877",
      "pubmed_id": "23453885"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52799203
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52799789
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52799789
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52799789
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52804386
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=11244",
        "NR=20899"
      ],
      "otg_id": "GCST002149",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST002149",
      "pubmed_id": "23974872"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (311318bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52811089
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 52811089
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000010322",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119431242
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001486"
      ],
      "reported_trait_name": "Primary biliary cholangitis",
      "standard_trait_name": "primary biliary cirrhosis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5158"
      ],
      "otg_id": "GCST004302",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST004302",
      "pubmed_id": "28425483"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (93052bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119455536
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=18264",
        "African American or Afro-Caribbean=5422",
        "Hispanic or Latin American=3888"
      ],
      "otg_id": "GCST005752",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST005752",
      "pubmed_id": "28714469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (68758bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119501087
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001486"
      ],
      "reported_trait_name": "Primary biliary cholangitis",
      "standard_trait_name": "primary biliary cirrhosis"
    },
    "association_info": {
      "ancestry": [
        "European=13239"
      ],
      "otg_id": "GCST003129",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST003129",
      "pubmed_id": "26394269"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119501087
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=26621"
      ],
      "otg_id": "GCST001198",
      "neg_log_pval": 8.96738123914928,
      "gwas_catalog_id": "GCST001198",
      "pubmed_id": "21833088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (23206bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119501087
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001486"
      ],
      "reported_trait_name": "Primary biliary cirrhosis",
      "standard_trait_name": "primary biliary cirrhosis"
    },
    "association_info": {
      "ancestry": [
        "European=11375"
      ],
      "otg_id": "GCST005581",
      "neg_log_pval": 15.16526148109616,
      "gwas_catalog_id": "GCST005581",
      "pubmed_id": "22961000"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119501087
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001486"
      ],
      "reported_trait_name": "Primary biliary cholangitis",
      "standard_trait_name": "primary biliary cirrhosis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=3574"
      ],
      "otg_id": "GCST007036",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST007036",
      "pubmed_id": "30643196"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119503609
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=18264"
      ],
      "otg_id": "GCST007400",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST007400",
      "pubmed_id": "28714469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (20684bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119525746
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 14.397940008672037,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119542097
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5050"
      ],
      "otg_id": "GCST001795",
      "neg_log_pval": 15.522878745280337,
      "gwas_catalog_id": "GCST001795",
      "pubmed_id": "23273568"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 119553544
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5050"
      ],
      "otg_id": "GCST002845",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST002845",
      "pubmed_id": "25862617"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000121594",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 121824730
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 14.154901959985743,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (230632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 121941817
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis and HDL levels (pleiotropy)",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "NR=215725"
      ],
      "otg_id": "GCST007124",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007124",
      "pubmed_id": "26920376"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (113546bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 121997324
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000114013 at this locus (58039bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 122050675
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=15283"
      ],
      "otg_id": "GCST003566",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST003566",
      "pubmed_id": "27386562"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (4687bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 122051692
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "NR=3599",
        "Hispanic or Latin American=1956",
        "European=17698"
      ],
      "otg_id": "GCST003340",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST003340",
      "pubmed_id": "26819262"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 122051692
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=38582"
      ],
      "otg_id": "GCST005531",
      "neg_log_pval": 12.273272790973428,
      "gwas_catalog_id": "GCST005531",
      "pubmed_id": "24076602"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "3",
        "position": 122077921
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003885"
      ],
      "reported_trait_name": "Multiple sclerosis",
      "standard_trait_name": "multiple sclerosis"
    },
    "association_info": {
      "ancestry": [
        "European=26621"
      ],
      "otg_id": "GCST001198",
      "neg_log_pval": 8.811915626285062,
      "gwas_catalog_id": "GCST001198",
      "pubmed_id": "21833088"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000114013",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 1732512
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000292"
      ],
      "reported_trait_name": "Urinary bladder cancer",
      "standard_trait_name": "bladder carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=41199"
      ],
      "otg_id": "GCST000639",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST000639",
      "pubmed_id": "20348956"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000068078",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 1732512
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000292"
      ],
      "reported_trait_name": "Bladder cancer",
      "standard_trait_name": "bladder carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=6206"
      ],
      "otg_id": "GCST002240",
      "neg_log_pval": 24.154901959985743,
      "gwas_catalog_id": "GCST002240",
      "pubmed_id": "24163127"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000068078",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 1732512
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000292"
      ],
      "reported_trait_name": "Bladder cancer",
      "standard_trait_name": "bladder carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=8652"
      ],
      "otg_id": "GCST000842",
      "neg_log_pval": 12.397940008672037,
      "gwas_catalog_id": "GCST000842",
      "pubmed_id": "20972438"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000068078",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 1767709
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000292"
      ],
      "reported_trait_name": "Bladder cancer | cancer code, self-reported",
      "standard_trait_name": "bladder carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20001_1035",
      "neg_log_pval": 7.692944898477948,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000068078",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (25584bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 45545051
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003829"
      ],
      "reported_trait_name": "Risky sexual behaviors in alcohol dependence [AA]",
      "standard_trait_name": "alcohol dependence"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1541",
        "European=1436"
      ],
      "otg_id": "GCST004955",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004955",
      "pubmed_id": "28990359"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug LORAZEPAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 45545051
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003829"
      ],
      "reported_trait_name": "Risky sexual behaviors in alcohol dependence [AA]",
      "standard_trait_name": "alcohol dependence"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1541",
        "European=1436"
      ],
      "otg_id": "GCST004955",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004955",
      "pubmed_id": "28990359"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel allosteric antagonist drug FLUMAZENIL is Phase II for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 45545051
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003829"
      ],
      "reported_trait_name": "Risky sexual behaviors in alcohol dependence [AA]",
      "standard_trait_name": "alcohol dependence"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1541",
        "European=1436"
      ],
      "otg_id": "GCST004955",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004955",
      "pubmed_id": "28990359"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug CHLORDIAZEPOXIDE is Phase III for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 46412095
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Alzheimer disease and age of onset [between families]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3524"
      ],
      "otg_id": "GCST003427",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST003427",
      "pubmed_id": "26830138"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000163285 at this locus (288042bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 46412095
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Alzheimer disease and age of onset [between families]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3524"
      ],
      "otg_id": "GCST003427",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST003427",
      "pubmed_id": "26830138"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151834",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 46541289
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=26405"
      ],
      "otg_id": "GCST000964",
      "neg_log_pval": 8.872895201635192,
      "gwas_catalog_id": "GCST000964",
      "pubmed_id": "21297633"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151834",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000151834 at this locus (66059bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 46541289
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=26405"
      ],
      "otg_id": "GCST000964",
      "neg_log_pval": 8.872895201635192,
      "gwas_catalog_id": "GCST000964",
      "pubmed_id": "21297633"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000163285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000163285 at this locus (417235bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 46689227
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000249"
      ],
      "reported_trait_name": "Alzheimer disease and age of onset [between families]",
      "standard_trait_name": "Alzheimer's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3524"
      ],
      "otg_id": "GCST003427",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST003427",
      "pubmed_id": "26830138"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151834",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (213998bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 87037243
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4275"
      ],
      "otg_id": "GCST001384",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST001384",
      "pubmed_id": "22291604"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000109339",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "c-Jun N-terminal kinase 3 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000109339 at this locus (442619bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89698581
      },
      "alleles": {
        "reference": "T",
        "alternative": "TA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinsons disease | non-cancer illness code, self-reported",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1262",
      "neg_log_pval": 9.056494107508188,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (25518bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89704960
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=334141"
      ],
      "otg_id": "GCST003984",
      "neg_log_pval": 56.0,
      "gwas_catalog_id": "GCST003984",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89704960
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=108990"
      ],
      "otg_id": "GCST002544",
      "neg_log_pval": 72.39794000867204,
      "gwas_catalog_id": "GCST002544",
      "pubmed_id": "25064009"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89704960
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=417508"
      ],
      "otg_id": "GCST004902",
      "neg_log_pval": 122.30102999566398,
      "gwas_catalog_id": "GCST004902",
      "pubmed_id": "28892059"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89716450
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease [EA]",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=4258"
      ],
      "otg_id": "GCST001445_2",
      "neg_log_pval": 64.22184874961636,
      "gwas_catalog_id": "GCST001445",
      "pubmed_id": "22438815"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89716450
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=17352"
      ],
      "otg_id": "GCST000959",
      "neg_log_pval": 46.69897000433602,
      "gwas_catalog_id": "GCST000959",
      "pubmed_id": "21292315"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89718364
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "East Asian=3509"
      ],
      "otg_id": "GCST000530",
      "neg_log_pval": 16.154901959985743,
      "gwas_catalog_id": "GCST000530",
      "pubmed_id": "19915576"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (5735bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=33050"
      ],
      "otg_id": "GCST001126",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST001126",
      "pubmed_id": "21738487"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease [Sporadic]",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3986"
      ],
      "otg_id": "GCST002353_3",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST002353",
      "pubmed_id": "24511991"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=8477"
      ],
      "otg_id": "GCST001430",
      "neg_log_pval": 34.096910013008056,
      "gwas_catalog_id": "GCST001430",
      "pubmed_id": "22451204"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3986"
      ],
      "otg_id": "GCST000772",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST000772",
      "pubmed_id": "20711177"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=6880"
      ],
      "otg_id": "GCST000855",
      "neg_log_pval": 15.045757490560675,
      "gwas_catalog_id": "GCST000855",
      "pubmed_id": "21044948"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3023"
      ],
      "otg_id": "GCST000874",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST000874",
      "pubmed_id": "21084426"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89720189
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=3986"
      ],
      "otg_id": "GCST002353",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002353",
      "pubmed_id": "24511991"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89723303
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "East Asian=14006"
      ],
      "otg_id": "GCST003922",
      "neg_log_pval": 32.0,
      "gwas_catalog_id": "GCST003922",
      "pubmed_id": "28011712"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (797bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89744890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease (age of onset)",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=17996"
      ],
      "otg_id": "GCST007780",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST007780",
      "pubmed_id": "30957308"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89757390
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "European=5691"
      ],
      "otg_id": "GCST000528",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST000528",
      "pubmed_id": "19915575"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 89859751
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002508"
      ],
      "reported_trait_name": "Parkinson's disease [Asian]",
      "standard_trait_name": "Parkinson's disease"
    },
    "association_info": {
      "ancestry": [
        "NR=4258"
      ],
      "otg_id": "GCST001445",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST001445",
      "pubmed_id": "22438815"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145335",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (21437bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 99318162
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 14.096910013008056,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000138823",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Microsomal triglyceride transfer protein inhibitor drug LOMITAPIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000138823 at this locus (245600bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 147479667
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004265"
      ],
      "reported_trait_name": "Peripheral artery disease",
      "standard_trait_name": "peripheral arterial disease"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4168"
      ],
      "otg_id": "GCST003154",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST003154",
      "pubmed_id": "26488411"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151617",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Endothelin receptor ET-A antagonist drug ZIBOTENTAN is Phase II for the indiciation EFO_0004265 and targets the gene ENSG00000151617 at this locus (1251bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148016386
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 10.878440155812498,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148016386
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148016386
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 10.878440155812498,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148016386
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148025539
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug CANRENONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 148025539
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000151623",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155499453
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (259540bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155512156
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.636910992288339,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155512156
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.636910992288339,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515355
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 9.962972120244226,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515355
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 9.962972120244226,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515355
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 9.962972120244226,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515365
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515365
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155515365
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155693032
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155693032
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155693032
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 22.476643793345207,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 21.397940008672037,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 21.397940008672037,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 21.397940008672037,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 22.476643793345207,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155714157
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 22.476643793345207,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155717421
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155717421
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155717421
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155718736
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155718736
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155718736
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155718736
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000061918 at this locus (40257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155721732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 16.378823718224965,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155721732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 16.32513885926219,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155721732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408343"
      ],
      "otg_id": "SAIGE_401",
      "neg_log_pval": 16.378823718224965,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155721732
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Essential hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=408089"
      ],
      "otg_id": "SAIGE_401_1",
      "neg_log_pval": 16.32513885926219,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155724361
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 9.669586226650809,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155724361
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 9.669586226650809,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155724361
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 9.669586226650809,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155725188
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (33805bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155725188
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 15.293624498063002,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155725188
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 15.293624498063002,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155745839
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "4",
        "position": 155745839
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension [East Asian]",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=50792"
      ],
      "otg_id": "GCST007707",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007707",
      "pubmed_id": "30487518"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000061918",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=30659"
      ],
      "otg_id": "GCST004347",
      "neg_log_pval": 65.52287874528034,
      "gwas_catalog_id": "GCST004347",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=3749",
        "European=5388"
      ],
      "otg_id": "GCST001298",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST001298",
      "pubmed_id": "22037553"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 73.09691001300806,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 73.09691001300806,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24009"
      ],
      "otg_id": "GCST004348",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST004348",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=15566"
      ],
      "otg_id": "GCST005075",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST005075",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24009"
      ],
      "otg_id": "GCST004348",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST004348",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=30659"
      ],
      "otg_id": "GCST004347",
      "neg_log_pval": 65.52287874528034,
      "gwas_catalog_id": "GCST004347",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 16.10874138309586,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST003228",
      "neg_log_pval": 19.397940008672037,
      "gwas_catalog_id": "GCST003228",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Invasive epithelial ovarian cancer",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63347"
      ],
      "otg_id": "GCST004415",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004415",
      "pubmed_id": "28346442"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=39387"
      ],
      "otg_id": "GCST001930",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST001930",
      "pubmed_id": "23535733"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=39387"
      ],
      "otg_id": "GCST001930",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST001930",
      "pubmed_id": "23535733"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 16.10874138309586,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=15566"
      ],
      "otg_id": "GCST005075",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST005075",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST003228",
      "neg_log_pval": 19.397940008672037,
      "gwas_catalog_id": "GCST003228",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279675
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=3749",
        "European=5388"
      ],
      "otg_id": "GCST001298",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST001298",
      "pubmed_id": "22037553"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279913
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 51.39794000867204,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279913
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 27.096910013008056,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (112882bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279913
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 27.096910013008056,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1279913
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 23.522878745280337,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1280715
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Cancer of brain and nervous system",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=407770"
      ],
      "otg_id": "SAIGE_191_1",
      "neg_log_pval": 8.411168274405792,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1280715
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Cancer of brain and nervous system",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=407770"
      ],
      "otg_id": "SAIGE_191_1",
      "neg_log_pval": 8.411168274405792,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282204
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110590bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282204
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (110495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (110495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Cancer (pleiotropy) [subset analysis]",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=123671"
      ],
      "otg_id": "GCST003588_2",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003588",
      "pubmed_id": "27197191"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1282299
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=7541"
      ],
      "otg_id": "GCST002890",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002890",
      "pubmed_id": "25939597"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1284538
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=291407"
      ],
      "otg_id": "GCST004142",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST004142",
      "pubmed_id": "28212542"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (108257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1285859
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Invasive epithelial ovarian cancer",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63347"
      ],
      "otg_id": "GCST004415",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST004415",
      "pubmed_id": "28346442"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (106936bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1285859
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002429"
      ],
      "reported_trait_name": "Polycythaemia vera | non-cancer illness code, self-reported",
      "standard_trait_name": "polycythemia vera"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1438",
      "neg_log_pval": 7.383947958952672,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000164362 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5408"
      ],
      "otg_id": "GCST001140",
      "neg_log_pval": 27.0,
      "gwas_catalog_id": "GCST001140",
      "pubmed_id": "21725308"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=4773"
      ],
      "otg_id": "GCST001194",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST001194",
      "pubmed_id": "21827660"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST001058",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST001058",
      "pubmed_id": "21531791"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma (high-grade)",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=7608"
      ],
      "otg_id": "GCST002474",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST002474",
      "pubmed_id": "24908248"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=5548"
      ],
      "otg_id": "GCST000439",
      "neg_log_pval": 16.69897000433602,
      "gwas_catalog_id": "GCST000439",
      "pubmed_id": "19578367"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=10054"
      ],
      "otg_id": "GCST001740",
      "neg_log_pval": 26.397940008672037,
      "gwas_catalog_id": "GCST001740",
      "pubmed_id": "23143601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=4773"
      ],
      "otg_id": "GCST001194",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST001194",
      "pubmed_id": "21827660"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=6811"
      ],
      "otg_id": "GCST001633",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001633",
      "pubmed_id": "22886559"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma (high-grade)",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=7608"
      ],
      "otg_id": "GCST002474",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST002474",
      "pubmed_id": "24908248"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=5548"
      ],
      "otg_id": "GCST000439",
      "neg_log_pval": 16.69897000433602,
      "gwas_catalog_id": "GCST000439",
      "pubmed_id": "19578367"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST001058",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST001058",
      "pubmed_id": "21531791"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1286401
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=6811"
      ],
      "otg_id": "GCST001633",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001633",
      "pubmed_id": "22886559"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1287079
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=5339"
      ],
      "otg_id": "GCST003775",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST003775",
      "pubmed_id": "27393504"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (105715bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1288432
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=5548"
      ],
      "otg_id": "GCST000439",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST000439",
      "pubmed_id": "19578367"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1288432
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=5548"
      ],
      "otg_id": "GCST000439",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST000439",
      "pubmed_id": "19578367"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1295234
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 20.392866795608434,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (166bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1295234
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 20.392866795608434,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (97561bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1297373
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1297373
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1297373
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1297373
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164362",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1315545
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=3390"
      ],
      "otg_id": "GCST000459",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST000459",
      "pubmed_id": "19654303"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (77250bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1320021
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer in ever smokers",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=40187"
      ],
      "otg_id": "GCST004749",
      "neg_log_pval": 16.522878745280337,
      "gwas_catalog_id": "GCST004749",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72773bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1320132
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=85716"
      ],
      "otg_id": "GCST004748",
      "neg_log_pval": 31.69897000433602,
      "gwas_catalog_id": "GCST004748",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72663bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1321972
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000756"
      ],
      "reported_trait_name": "Melanoma",
      "standard_trait_name": "melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=10422"
      ],
      "otg_id": "GCST001267",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001267",
      "pubmed_id": "21983787"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (70822bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1321972
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=10295"
      ],
      "otg_id": "GCST000257",
      "neg_log_pval": 8.096910013008056,
      "gwas_catalog_id": "GCST000257",
      "pubmed_id": "18978787"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (70822bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1339775
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer | illnesses of father",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=314072"
      ],
      "otg_id": "NEALE2_20107_3",
      "neg_log_pval": 10.406891232219362,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (53019bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1442864
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004698"
      ],
      "reported_trait_name": "Sleeplessness / insomnia",
      "standard_trait_name": "insomnia"
    },
    "association_info": {
      "ancestry": [
        "European=360738"
      ],
      "otg_id": "NEALE2_1200",
      "neg_log_pval": 7.9587810673873625,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug MODAFINIL is Phase IV for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1442864
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004698"
      ],
      "reported_trait_name": "Sleeplessness / insomnia",
      "standard_trait_name": "insomnia"
    },
    "association_info": {
      "ancestry": [
        "European=360738"
      ],
      "otg_id": "NEALE2_1200",
      "neg_log_pval": 7.9587810673873625,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1895715
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4969"
      ],
      "otg_id": "GCST000750",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST000750",
      "pubmed_id": "20676098"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 1895715
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7394"
      ],
      "otg_id": "GCST003148",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST003148",
      "pubmed_id": "26443449"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000142319",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 40347367
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European, NR=45975"
      ],
      "otg_id": "GCST004133",
      "neg_log_pval": 8.104080454689985,
      "gwas_catalog_id": "GCST004133",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171522",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (332548bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 40414784
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 11.43486084803021,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171522",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265131bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 40414887
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 74.0,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171522",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 40487168
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000171522",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (192747bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 43054645
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003888"
      ],
      "reported_trait_name": "Attention deficit hyperactivity disorder or cannabis use",
      "standard_trait_name": "attention deficit hyperactivity disorder"
    },
    "association_info": {
      "ancestry": [
        "European=83129"
      ],
      "otg_id": "GCST006983",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST006983",
      "pubmed_id": "30610198"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112964",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Growth hormone receptor agonist drug SOMATROPIN is Phase IV for the indiciation EFO_0003888 and targets the gene ENSG00000112964 at this locus (332768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 64440647
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000178394",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serotonin 1a (5-HT1a) receptor agonist drug ERGOLOID is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000178394 at this locus (478140bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75309395
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003774"
      ],
      "reported_trait_name": "Hyperlipidemia",
      "standard_trait_name": "hyperlipidemia"
    },
    "association_info": {
      "ancestry": [
        "European=408878"
      ],
      "otg_id": "SAIGE_272_1",
      "neg_log_pval": 15.436518914605589,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000113161 at this locus (26934bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75309395
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "Hypercholesterolemia",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=406276"
      ],
      "otg_id": "SAIGE_272_11",
      "neg_log_pval": 14.154901959985743,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (26934bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75309395
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 15.410050398674292,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75309395
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_309005"
      ],
      "reported_trait_name": "Disorders of lipoid metabolism",
      "standard_trait_name": "Disorder of lipid metabolism"
    },
    "association_info": {
      "ancestry": [
        "European=408961"
      ],
      "otg_id": "SAIGE_272",
      "neg_log_pval": 15.410050398674292,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug LOVASTATIN is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003144"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "heart failure"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75329662
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001645"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "coronary heart disease"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (6667bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75360714
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000113161 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75360714
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 42.19124767849288,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001645"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "coronary heart disease"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003144"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "heart failure"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75463358
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (101258bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001645"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "coronary heart disease"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003144"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "heart failure"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000311"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "cancer"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75584065
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000400"
      ],
      "reported_trait_name": "Age-related diseases, mortality and associated endophenotypes",
      "standard_trait_name": "diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=9618"
      ],
      "otg_id": "GCST004045",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004045",
      "pubmed_id": "27790247"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (221964bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75707853
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75707853
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957",
        "South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287"
      ],
      "otg_id": "GCST007515",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST007515",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75707853
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=298957"
      ],
      "otg_id": "GCST007517",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST007517",
      "pubmed_id": "29632382"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75707853
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Obesity class I]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_4",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (345752bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75719417
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Obesity class II]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_3",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 75719417
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001073"
      ],
      "reported_trait_name": "Obesity [Overweight]",
      "standard_trait_name": "obesity"
    },
    "association_info": {
      "ancestry": [
        "European=204498"
      ],
      "otg_id": "GCST001953_5",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST001953",
      "pubmed_id": "23563607"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113161",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110807116
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110807116
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110807116
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=102453"
      ],
      "otg_id": "GCST007563",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST007563",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110807116
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=102453"
      ],
      "otg_id": "GCST007563",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST007563",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110823145
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 7.835647144215563,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110823145
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 7.835647144215563,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 7.755663492560309,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 7.755663492560309,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 17.72690377259096,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 17.72690377259096,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 19.160999247384563,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Age hay fever, rhinitis or eczema diagnosed",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=72232"
      ],
      "otg_id": "NEALE2_3761_raw",
      "neg_log_pval": 8.280520382028882,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110825774
      },
      "alleles": {
        "reference": "C",
        "alternative": "CA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 19.160999247384563,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110862415
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.097453220686008,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 110862415
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.097453220686008,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 7.8621333944441085,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 20.97469413473523,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 36.21098861481695,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 30.522878745280337,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 7.8621333944441085,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 30.522878745280337,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1612",
        "European=2088",
        "Hispanic or Latin American=1688"
      ],
      "otg_id": "GCST001182",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST001182",
      "pubmed_id": "21804549"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 37.65559397059892,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=1612",
        "European=2088",
        "Hispanic or Latin American=1688"
      ],
      "otg_id": "GCST001182",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST001182",
      "pubmed_id": "21804549"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 21.00267741002066,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 20.397940008672037,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 26.016373712875467,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 20.97469413473523,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 20.397940008672037,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 41.0,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma and hay fever",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=20776"
      ],
      "otg_id": "GCST002322",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST002322",
      "pubmed_id": "24388013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 37.65559397059892,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 41.0,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 21.69897000433602,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma and hay fever",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=20776"
      ],
      "otg_id": "GCST002322",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST002322",
      "pubmed_id": "24388013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4836"
      ],
      "otg_id": "GCST001183",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST001183",
      "pubmed_id": "21804548"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 14.301029995663981,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=4836"
      ],
      "otg_id": "GCST001183",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST001183",
      "pubmed_id": "21804548"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 26.016373712875467,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 21.69897000433602,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 21.00267741002066,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 36.21098861481695,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111066174
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 14.301029995663981,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111069301
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 25.045757490560675,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111069301
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 25.045757490560675,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111069301
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 24.692503962086786,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111069301
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 24.692503962086786,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111071044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 18.959010211096686,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111071044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 18.959010211096686,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111071044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 20.137288556960716,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111071044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 20.137288556960716,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma and hay fever",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=20776"
      ],
      "otg_id": "GCST002322",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002322",
      "pubmed_id": "24388013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 12.522878745280337,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=102453"
      ],
      "otg_id": "GCST007563",
      "neg_log_pval": 19.30102999566398,
      "gwas_catalog_id": "GCST007563",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Allergic disease (asthma, hay fever or eczema)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=102453"
      ],
      "otg_id": "GCST007563",
      "neg_log_pval": 19.30102999566398,
      "gwas_catalog_id": "GCST007563",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111131801
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma and hay fever",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=20776"
      ],
      "otg_id": "GCST002322",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002322",
      "pubmed_id": "24388013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111134439
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 18.149353764816933,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111134439
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 18.149353764816933,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 111135520
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Age hay fever, rhinitis or eczema diagnosed",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=72232"
      ],
      "otg_id": "NEALE2_3761_raw",
      "neg_log_pval": 8.814540009081632,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145777",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (57494bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132094425
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=20965"
      ],
      "otg_id": "GCST001454",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST001454",
      "pubmed_id": "22446963"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000164400 at this locus (18255bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132333468
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 25.175982286576183,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (322795bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132333468
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 46.705144404319334,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (322795bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132340627
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1000391"
      ],
      "reported_trait_name": "Nasal polyps",
      "standard_trait_name": "Nasal Cavity Polyp"
    },
    "association_info": {
      "ancestry": [
        "European=719047"
      ],
      "otg_id": "GCST007443",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST007443",
      "pubmed_id": "30643255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (200819bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132374707
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1000391"
      ],
      "reported_trait_name": "Nasal polyps",
      "standard_trait_name": "Nasal Cavity Polyp"
    },
    "association_info": {
      "ancestry": [
        "European=393356"
      ],
      "otg_id": "SAIGE_471",
      "neg_log_pval": 9.707743928643524,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (166739bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132396764
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 25.162379159732975,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (259500bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132435113
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 35.25274360255786,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132435113
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=9541"
      ],
      "otg_id": "GCST000207",
      "neg_log_pval": 17.69897000433602,
      "gwas_catalog_id": "GCST000207",
      "pubmed_id": "18587394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132442760
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 54.69897000433602,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (213503bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132442760
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 54.69897000433602,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (213503bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132442760
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 54.69897000433602,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (366590bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132442760
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 54.69897000433602,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (366590bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132448701
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=21389"
      ],
      "otg_id": "GCST000879",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST000879",
      "pubmed_id": "21102463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132448701
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=34366"
      ],
      "otg_id": "GCST001729",
      "neg_log_pval": 19.496209316942817,
      "gwas_catalog_id": "GCST001729",
      "pubmed_id": "23128233"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132461230
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 10.237794241945119,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (195033bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132461855
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.667561540084394,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (79591bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132461855
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.667561540084394,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132461855
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.667561540084394,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132461855
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 10.667561540084394,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (212132bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463681
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 7.620391669707774,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (387511bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 26.061318695302564,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 9.563837352959244,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 26.061318695302564,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 26.061318695302564,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 9.563837352959244,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 9.563837352959244,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 27.398007329534234,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 27.398007329534234,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 27.398007329534234,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 13.221848749616356,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 27.398007329534234,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 9.563837352959244,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132463934
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 26.061318695302564,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132472976
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (68469bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132472976
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (201010bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132472976
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132472976
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132475490
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (180773bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132475490
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (180773bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132475490
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (399320bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132475490
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164400",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (399320bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132490630
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 11.05858795962645,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (50815bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132490630
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 11.05858795962645,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132490630
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 11.05858795962645,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (183357bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132490630
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Doctor diagnosed asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=91787"
      ],
      "otg_id": "NEALE2_22127",
      "neg_log_pval": 11.05858795962645,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132552294
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132552294
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132552294
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132552294
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma (moderate or severe)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=30810"
      ],
      "otg_id": "GCST006911",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST006911",
      "pubmed_id": "30552067"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (121692bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132565533
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132565533
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (8696bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132565533
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132565533
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (108454bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 31.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 26.939774475605834,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 28.044273294785736,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 31.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 28.044273294785736,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 31.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 26.939774475605834,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 28.044273294785736,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 26.939774475605834,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma onset (childhood vs adult)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=28835"
      ],
      "otg_id": "GCST007797",
      "neg_log_pval": 8.154901959985743,
      "gwas_catalog_id": "GCST007797",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 28.044273294785736,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 26.939774475605834,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132581248
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 31.154901959985743,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132589495
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (84491bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132589495
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132589495
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (32657bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132589495
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=90853"
      ],
      "otg_id": "GCST007562",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST007562",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132616530
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Inflammatory skin disease [Opposed]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_3",
      "neg_log_pval": 17.69897000433602,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132616530
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Inflammatory skin disease [Opposed]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_3",
      "neg_log_pval": 17.69897000433602,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132619885
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005854"
      ],
      "reported_trait_name": "Allergic rhinitis",
      "standard_trait_name": "allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "NR, European=212120"
      ],
      "otg_id": "GCST006409",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006409",
      "pubmed_id": "30013184"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132619885
      },
      "alleles": {
        "reference": "T",
        "alternative": "TATATATATATAG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005854"
      ],
      "reported_trait_name": "Allergic rhinitis",
      "standard_trait_name": "allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "NR, European=212120"
      ],
      "otg_id": "GCST006409",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006409",
      "pubmed_id": "30013184"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132619885
      },
      "alleles": {
        "reference": "T",
        "alternative": "TAGAG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005854"
      ],
      "reported_trait_name": "Allergic rhinitis",
      "standard_trait_name": "allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "NR, European=212120"
      ],
      "otg_id": "GCST006409",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006409",
      "pubmed_id": "30013184"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132619885
      },
      "alleles": {
        "reference": "T",
        "alternative": "TAG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005854"
      ],
      "reported_trait_name": "Allergic rhinitis",
      "standard_trait_name": "allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "NR, European=212120"
      ],
      "otg_id": "GCST006409",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006409",
      "pubmed_id": "30013184"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132619885
      },
      "alleles": {
        "reference": "T",
        "alternative": "TAA"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005854"
      ],
      "reported_trait_name": "Allergic rhinitis",
      "standard_trait_name": "allergic rhinitis"
    },
    "association_info": {
      "ancestry": [
        "NR, European=212120"
      ],
      "otg_id": "GCST006409",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006409",
      "pubmed_id": "30013184"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132655393
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [EA, fixed effects]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184",
      "neg_log_pval": 16.397940008672037,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132655393
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [EA, fixed effects]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184",
      "neg_log_pval": 16.397940008672037,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132656189
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 15.5654310959658,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132656189
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 15.5654310959658,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (99351bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132656189
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 15.5654310959658,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132656189
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=401837"
      ],
      "otg_id": "SAIGE_495",
      "neg_log_pval": 15.5654310959658,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (17797bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660151
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=5617"
      ],
      "otg_id": "GCST002100",
      "neg_log_pval": 16.69897000433602,
      "gwas_catalog_id": "GCST002100",
      "pubmed_id": "23886662"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660151
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=5946"
      ],
      "otg_id": "GCST002737",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST002737",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660151
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=5617"
      ],
      "otg_id": "GCST002100",
      "neg_log_pval": 16.69897000433602,
      "gwas_catalog_id": "GCST002100",
      "pubmed_id": "23886662"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660151
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=5946"
      ],
      "otg_id": "GCST002737",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST002737",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 13.853871964321762,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 13.853871964321762,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 13.853871964321762,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660272
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=127669"
      ],
      "otg_id": "GCST006862",
      "neg_log_pval": 13.853871964321762,
      "gwas_catalog_id": "GCST006862",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132660808
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004192"
      ],
      "reported_trait_name": "Alopecia areata",
      "standard_trait_name": "alopecia areata"
    },
    "association_info": {
      "ancestry": [
        "European=7565"
      ],
      "otg_id": "GCST004866",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004866",
      "pubmed_id": "25608926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase II for the indiciation EFO_0004192 and targets the gene ENSG00000169194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132693166
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [conditional on rs6419573]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184_2",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132693166
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [conditional on rs6419573]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184_2",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132694975
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic march",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=11181"
      ],
      "otg_id": "GCST003180",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST003180",
      "pubmed_id": "26542096"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132694975
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic march",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=11181"
      ],
      "otg_id": "GCST003180",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST003180",
      "pubmed_id": "26542096"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132713335
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [EA, fixed effects]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132713335
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=26171"
      ],
      "otg_id": "GCST001363",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST001363",
      "pubmed_id": "22197932"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132713335
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis [EA, fixed effects]",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=103066",
        "Hispanic or Latin American=1892",
        "African American or Afro-Caribbean=1266",
        "East Asian=9438",
        "NR=1201"
      ],
      "otg_id": "GCST003184",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST003184",
      "pubmed_id": "26482879"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132713335
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic dermatitis",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=26171"
      ],
      "otg_id": "GCST001363",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST001363",
      "pubmed_id": "22197932"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132721182
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 8.737359096244738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132721182
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 8.737359096244738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132721182
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 8.737359096244738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (38505bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132721182
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Age asthma diagnosed",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=36955"
      ],
      "otg_id": "NEALE2_3786_raw",
      "neg_log_pval": 8.737359096244738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (164345bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132724891
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113525",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (168054bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132724891
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (42213bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132724891
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 132724891
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 133103318
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 133103318
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143270839
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143270839
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143270839
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143270839
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143500967
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 16.716472635138306,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug METHYLPREDNISOLONE HEMISUCCINATE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 143500967
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 16.716472635138306,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113580",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148475407
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 32.52287874528034,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148475407
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 32.52287874528034,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor partial agonist drug CELIPROLOL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148475407
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692",
      "neg_log_pval": 32.52287874528034,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=3522",
        "Hispanic or Latin American=600",
        "European=47856",
        "East Asian=6940"
      ],
      "otg_id": "GCST004147",
      "neg_log_pval": 25.30102999566398,
      "gwas_catalog_id": "GCST004147",
      "pubmed_id": "28166215"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=3522",
        "Hispanic or Latin American=600",
        "European=47856",
        "East Asian=6940"
      ],
      "otg_id": "GCST004147",
      "neg_log_pval": 25.30102999566398,
      "gwas_catalog_id": "GCST004147",
      "pubmed_id": "28166215"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European, NR=58918",
        "European=458554"
      ],
      "otg_id": "GCST007611",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST007611",
      "pubmed_id": "30940143"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor antagonist drug PROPRANOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148476770
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=3522",
        "Hispanic or Latin American=600",
        "European=47856",
        "East Asian=6940"
      ],
      "otg_id": "GCST004147",
      "neg_log_pval": 25.30102999566398,
      "gwas_catalog_id": "GCST004147",
      "pubmed_id": "28166215"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 148967980
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.715497077748008,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169252",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Beta-2 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (139293bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 149816671
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000182578",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Macrophage colony stimulating factor receptor inhibitor drug VATALANIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000182578 at this locus (236621bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 149816671
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113721",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Platelet-derived growth factor receptor beta inhibitor drug DASATINIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 149816671
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000389"
      ],
      "reported_trait_name": "Nevus count or cutaneous melanoma",
      "standard_trait_name": "skin melanoma"
    },
    "association_info": {
      "ancestry": [
        "European=88583"
      ],
      "otg_id": "GCST007505",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST007505",
      "pubmed_id": "30429480"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113721",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Platelet-derived growth factor receptor beta inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159242905
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 10.388393510619363,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159242905
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 10.388393510619363,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159290781
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 27.69897000433602,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159290781
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Cutaneous psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=6297"
      ],
      "otg_id": "GCST003269",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST003269",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159290781
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 27.69897000433602,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159290781
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Cutaneous psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=6297"
      ],
      "otg_id": "GCST003269",
      "neg_log_pval": 13.0,
      "gwas_catalog_id": "GCST003269",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159322080
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [conditional on rs7709212, rs4921493]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_10",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159322080
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [conditional on rs7709212, rs4921493]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_10",
      "neg_log_pval": 9.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159322080
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA, conditional on rs7709212, rs4921493]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_6",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159322080
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA, conditional on rs7709212, rs4921493]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_6",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159323761
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159323761
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2271"
      ],
      "otg_id": "GCST000321",
      "neg_log_pval": 25.522878745280337,
      "gwas_catalog_id": "GCST000321",
      "pubmed_id": "19169255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159323761
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159323761
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2271"
      ],
      "otg_id": "GCST000321",
      "neg_log_pval": 25.522878745280337,
      "gwas_catalog_id": "GCST000321",
      "pubmed_id": "19169255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159328837
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthropathy",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=398907"
      ],
      "otg_id": "SAIGE_696_42",
      "neg_log_pval": 8.0268721464003,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159332892
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 34.52287874528034,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159332892
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=1618"
      ],
      "otg_id": "GCST000836",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST000836",
      "pubmed_id": "20953188"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159332892
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=1618"
      ],
      "otg_id": "GCST000836",
      "neg_log_pval": 20.0,
      "gwas_catalog_id": "GCST000836",
      "pubmed_id": "20953188"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159332892
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Inflammatory skin disease [Psoriasis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=18190"
      ],
      "otg_id": "GCST002740_4",
      "neg_log_pval": 34.52287874528034,
      "gwas_catalog_id": "GCST002740",
      "pubmed_id": "25574825"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_8",
      "neg_log_pval": 19.522878745280337,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [Chinese]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_3",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [Chinese, conditional on rs1990760]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_2",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [Chinese]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_3",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_8",
      "neg_log_pval": 19.522878745280337,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 29.69897000433602,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [Chinese, conditional on rs1990760]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_2",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337169
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874",
      "neg_log_pval": 29.69897000433602,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159337470
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=6880"
      ],
      "otg_id": "GCST003270",
      "neg_log_pval": 24.0,
      "gwas_catalog_id": "GCST003270",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (6584bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159339014
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 22.400348322298537,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159339014
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 22.400348322298537,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159341357
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2198"
      ],
      "otg_id": "GCST007043",
      "neg_log_pval": 9.045757490560675,
      "gwas_catalog_id": "GCST007043",
      "pubmed_id": "30552173"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (10470bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159344329
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 33.5271134750456,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159344329
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 33.5271134750456,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159347957
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 16.91802094893202,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159347957
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European, NR=45975"
      ],
      "otg_id": "GCST004133",
      "neg_log_pval": 19.67571754470231,
      "gwas_catalog_id": "GCST004133",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159360377
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=21389"
      ],
      "otg_id": "GCST000879",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST000879",
      "pubmed_id": "21102463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159360377
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=21389"
      ],
      "otg_id": "GCST000879",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST000879",
      "pubmed_id": "21102463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159371067
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 19.061080187755227,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159371067
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 19.061080187755227,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159383785
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 20.03839715731701,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159383785
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 20.03839715731701,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159387525
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=9541"
      ],
      "otg_id": "GCST000207",
      "neg_log_pval": 12.397940008672037,
      "gwas_catalog_id": "GCST000207",
      "pubmed_id": "18587394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159387525
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=9541"
      ],
      "otg_id": "GCST000207",
      "neg_log_pval": 12.397940008672037,
      "gwas_catalog_id": "GCST000207",
      "pubmed_id": "18587394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159391737
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=11802"
      ],
      "otg_id": "GCST001149",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001149",
      "pubmed_id": "21743469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (60850bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159393053
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400436"
      ],
      "otg_id": "SAIGE_696_4",
      "neg_log_pval": 13.292429823902063,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159393053
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400436"
      ],
      "otg_id": "SAIGE_696_4",
      "neg_log_pval": 13.292429823902063,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159394909
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 13.017728766960431,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159394909
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 13.017728766960431,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159399302
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis and related disorders",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400492"
      ],
      "otg_id": "SAIGE_696",
      "neg_log_pval": 20.714442690992225,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159399302
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis and related disorders",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400492"
      ],
      "otg_id": "SAIGE_696",
      "neg_log_pval": 20.714442690992225,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159399784
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (68897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159399784
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European, NR=45975"
      ],
      "otg_id": "GCST004133",
      "neg_log_pval": 23.22951619056889,
      "gwas_catalog_id": "GCST004133",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159399784
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=26405"
      ],
      "otg_id": "GCST000964",
      "neg_log_pval": 7.991399828238082,
      "gwas_catalog_id": "GCST000964",
      "pubmed_id": "21297633"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis [EA]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=27432"
      ],
      "otg_id": "GCST003045",
      "neg_log_pval": 26.13838459401752,
      "gwas_catalog_id": "GCST003045",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 40.64029045008325,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease [EA]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=20883"
      ],
      "otg_id": "GCST003044",
      "neg_log_pval": 40.64029045008325,
      "gwas_catalog_id": "GCST003044",
      "pubmed_id": "26192919"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159400761
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402281
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400436"
      ],
      "otg_id": "SAIGE_696_4",
      "neg_log_pval": 19.950781977329818,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402281
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=400436"
      ],
      "otg_id": "SAIGE_696_4",
      "neg_log_pval": 19.950781977329818,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 28.860120913598763,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402286
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=40266"
      ],
      "otg_id": "GCST004132",
      "neg_log_pval": 28.860120913598763,
      "gwas_catalog_id": "GCST004132",
      "pubmed_id": "28067908"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 32.77779353908738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=1460"
      ],
      "otg_id": "GCST000835",
      "neg_log_pval": 16.154901959985743,
      "gwas_catalog_id": "GCST000835",
      "pubmed_id": "20953186"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1453",
      "neg_log_pval": 32.77779353908738,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 83.52287874528034,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 12.669586226650809,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 12.669586226650809,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthropathy | non-cancer illness code, self-reported",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1477",
      "neg_log_pval": 11.735654492949907,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 83.52287874528034,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159402519
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthropathy",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=398907"
      ],
      "otg_id": "SAIGE_696_42",
      "neg_log_pval": 10.665546248849068,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159405269
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_797"
      ],
      "reported_trait_name": "Sarcoidosis [EA]",
      "standard_trait_name": "Sarcoidosis"
    },
    "association_info": {
      "ancestry": [
        "European=7208"
      ],
      "otg_id": "GCST005538",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST005538",
      "pubmed_id": "26051272"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000113302 at this locus (74382bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159409099
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [conditional on rs7709212]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_11",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159409099
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA, conditional on rs7709212]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_7",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159409099
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [conditional on rs7709212]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_11",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 159409099
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis [EA, conditional on rs7709212]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5134",
        "European=8682"
      ],
      "otg_id": "GCST002874_7",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST002874",
      "pubmed_id": "25903422"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113302",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145863",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145863 at this locus (281691bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000022355",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug ALPRAZOLAM is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145864",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000022355",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113327",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000113327",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug CLORAZEPIC ACID is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "5",
        "position": 161984283
      },
      "alleles": {
        "reference": "CA",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005230"
      ],
      "reported_trait_name": "Worrier / anxious feelings",
      "standard_trait_name": "anxiety"
    },
    "association_info": {
      "ancestry": [
        "European=351833"
      ],
      "otg_id": "NEALE2_1980",
      "neg_log_pval": 8.322648589788734,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000145864",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "GABA-A receptor; anion channel positive allosteric modulator drug CLOMETHIAZOLE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 2969044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=10767"
      ],
      "otg_id": "GCST003468",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003468",
      "pubmed_id": "26956414"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137285 at this locus (255233bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 2969044
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000095"
      ],
      "reported_trait_name": "Chronic lymphocytic leukemia",
      "standard_trait_name": "chronic lymphocytic leukemia"
    },
    "association_info": {
      "ancestry": [
        "European=10767"
      ],
      "otg_id": "GCST003468",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003468",
      "pubmed_id": "26956414"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137267 at this locus (184622bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [serous]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_9",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137267",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 3580855
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001075"
      ],
      "reported_trait_name": "Epithelial ovarian cancer [HGSOC]",
      "standard_trait_name": "ovarian carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7321"
      ],
      "otg_id": "GCST007728_2",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST007728",
      "pubmed_id": "30898391"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000137285",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30374976
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer in ever smokers",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=40187"
      ],
      "otg_id": "GCST004749",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST004749",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30374976
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer in ever smokers",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=40187"
      ],
      "otg_id": "GCST004749",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST004749",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30383571
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000708"
      ],
      "reported_trait_name": "Squamous cell lung carcinoma",
      "standard_trait_name": "squamous cell lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63053"
      ],
      "otg_id": "GCST004750",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST004750",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30383571
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000708"
      ],
      "reported_trait_name": "Squamous cell lung carcinoma",
      "standard_trait_name": "squamous cell lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63053"
      ],
      "otg_id": "GCST004750",
      "neg_log_pval": 13.522878745280337,
      "gwas_catalog_id": "GCST004750",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30389517
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=85716"
      ],
      "otg_id": "GCST004748",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST004748",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30389517
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=85716"
      ],
      "otg_id": "GCST004748",
      "neg_log_pval": 17.397940008672037,
      "gwas_catalog_id": "GCST004748",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30633455
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30633455
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30633455
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30896502
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=85716"
      ],
      "otg_id": "GCST004748",
      "neg_log_pval": 18.154901959985743,
      "gwas_catalog_id": "GCST004748",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30896502
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=85716"
      ],
      "otg_id": "GCST004748",
      "neg_log_pval": 18.154901959985743,
      "gwas_catalog_id": "GCST004748",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30914638
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000708"
      ],
      "reported_trait_name": "Squamous cell lung carcinoma",
      "standard_trait_name": "squamous cell lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63053"
      ],
      "otg_id": "GCST004750",
      "neg_log_pval": 15.522878745280337,
      "gwas_catalog_id": "GCST004750",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30914638
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000708"
      ],
      "reported_trait_name": "Squamous cell lung carcinoma",
      "standard_trait_name": "squamous cell lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=63053"
      ],
      "otg_id": "GCST004750",
      "neg_log_pval": 15.522878745280337,
      "gwas_catalog_id": "GCST004750",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 30948482
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=287323"
      ],
      "otg_id": "GCST004346",
      "neg_log_pval": 324.22184874961636,
      "gwas_catalog_id": "GCST004346",
      "pubmed_id": "28537254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (223056bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31042408
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005842"
      ],
      "reported_trait_name": "Colorectal cancer or advanced adenoma",
      "standard_trait_name": "colorectal cancer"
    },
    "association_info": {
      "ancestry": [
        "European=120184",
        "East Asian=5294"
      ],
      "otg_id": "GCST007856",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST007856",
      "pubmed_id": "30510241"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000196230 at this locus (316982bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31057031
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000180"
      ],
      "reported_trait_name": "HIV-1 control [AA]",
      "standard_trait_name": "HIV-1 infection"
    },
    "association_info": {
      "ancestry": [
        "European=1712",
        "African American or Afro-Caribbean=1233",
        "Hispanic or Latin American=677"
      ],
      "otg_id": "GCST000863",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST000863",
      "pubmed_id": "21051598"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (331606bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31090401
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003780"
      ],
      "reported_trait_name": "Behcet's disease",
      "standard_trait_name": "Behcet's syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1098"
      ],
      "otg_id": "GCST001768",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST001768",
      "pubmed_id": "23001997"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (364975bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31090401
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003780"
      ],
      "reported_trait_name": "Behcet's disease",
      "standard_trait_name": "Behcet's syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1098"
      ],
      "otg_id": "GCST001768",
      "neg_log_pval": 11.0,
      "gwas_catalog_id": "GCST001768",
      "pubmed_id": "23001997"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (485164bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31106253
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000096"
      ],
      "reported_trait_name": "Follicular lymphoma",
      "standard_trait_name": "neoplasm of mature B-cells"
    },
    "association_info": {
      "ancestry": [
        "European=781"
      ],
      "otg_id": "GCST000448",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST000448",
      "pubmed_id": "19620980"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000096 and targets the gene ENSG00000196230 at this locus (380827bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31112239
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_797"
      ],
      "reported_trait_name": "Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)",
      "standard_trait_name": "Sarcoidosis"
    },
    "association_info": {
      "ancestry": [
        "European=1048"
      ],
      "otg_id": "GCST005541",
      "neg_log_pval": 26.096910013008056,
      "gwas_catalog_id": "GCST005541",
      "pubmed_id": "26651848"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31112239
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_797"
      ],
      "reported_trait_name": "Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)",
      "standard_trait_name": "Sarcoidosis"
    },
    "association_info": {
      "ancestry": [
        "European=1048"
      ],
      "otg_id": "GCST005541",
      "neg_log_pval": 26.096910013008056,
      "gwas_catalog_id": "GCST005541",
      "pubmed_id": "26651848"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31113428
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer in ever smokers",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=40187"
      ],
      "otg_id": "GCST004749",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST004749",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31113428
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer in ever smokers",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=40187"
      ],
      "otg_id": "GCST004749",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST004749",
      "pubmed_id": "28604730"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31120368
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Adult asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=8970",
        "African American or Afro-Caribbean=2025"
      ],
      "otg_id": "GCST003833",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST003833",
      "pubmed_id": "27611488"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (455197bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31121931
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis [Turkish]",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=978",
        "European=1112"
      ],
      "otg_id": "GCST006575_3",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST006575",
      "pubmed_id": "25604533"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (453635bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31131800
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003780"
      ],
      "reported_trait_name": "Behcet's disease",
      "standard_trait_name": "Behcet's syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1098"
      ],
      "otg_id": "GCST001768",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST001768",
      "pubmed_id": "23001997"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (443766bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31131800
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003780"
      ],
      "reported_trait_name": "Behcet's disease",
      "standard_trait_name": "Behcet's syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1098"
      ],
      "otg_id": "GCST001768",
      "neg_log_pval": 19.69897000433602,
      "gwas_catalog_id": "GCST001768",
      "pubmed_id": "23001997"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (406375bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31135187
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (440378bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31137636
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (437929bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31137636
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (437929bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31139481
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=9641"
      ],
      "otg_id": "GCST002140",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002140",
      "pubmed_id": "23955597"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31139481
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=9641"
      ],
      "otg_id": "GCST002140",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002140",
      "pubmed_id": "23955597"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31143579
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1310"
      ],
      "otg_id": "GCST000529",
      "neg_log_pval": 66.39794000867204,
      "gwas_catalog_id": "GCST000529",
      "pubmed_id": "19915573"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31143579
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1310"
      ],
      "otg_id": "GCST000529",
      "neg_log_pval": 66.39794000867204,
      "gwas_catalog_id": "GCST000529",
      "pubmed_id": "19915573"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31148749
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=241704"
      ],
      "otg_id": "GCST004483",
      "neg_log_pval": 16.522878745280337,
      "gwas_catalog_id": "GCST004483",
      "pubmed_id": "27363682"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31148749
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=241704"
      ],
      "otg_id": "GCST004483",
      "neg_log_pval": 16.522878745280337,
      "gwas_catalog_id": "GCST004483",
      "pubmed_id": "27363682"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31150734
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31150734
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31150734
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31168676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004775"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "toxic epidermal necrolysis"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (406890bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31168676
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004276"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "Stevens-Johnson syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (406890bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31174468
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004276"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "Stevens-Johnson syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (401097bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31174468
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004775"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "toxic epidermal necrolysis"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (401097bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31175805
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000180"
      ],
      "reported_trait_name": "HIV-1 control [EA]",
      "standard_trait_name": "HIV-1 infection"
    },
    "association_info": {
      "ancestry": [
        "European=1712",
        "African American or Afro-Caribbean=1233",
        "Hispanic or Latin American=677"
      ],
      "otg_id": "GCST000863_2",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST000863",
      "pubmed_id": "21051598"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (450379bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31188008
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2271"
      ],
      "otg_id": "GCST000321",
      "neg_log_pval": 207.69897000433602,
      "gwas_catalog_id": "GCST000321",
      "pubmed_id": "19169255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31188008
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2271"
      ],
      "otg_id": "GCST000321",
      "neg_log_pval": 207.69897000433602,
      "gwas_catalog_id": "GCST000321",
      "pubmed_id": "19169255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31188008
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2271"
      ],
      "otg_id": "GCST000321",
      "neg_log_pval": 207.69897000433602,
      "gwas_catalog_id": "GCST000321",
      "pubmed_id": "19169255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196230",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (462582bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31272654
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [SP-D]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_7",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31272654
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease-related biomarkers [SP-D]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European=1951"
      ],
      "otg_id": "GCST001737_7",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001737",
      "pubmed_id": "23144326"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31273332
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=1460"
      ],
      "otg_id": "GCST000835",
      "neg_log_pval": 71.69897000433602,
      "gwas_catalog_id": "GCST000835",
      "pubmed_id": "20953186"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31273332
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=1460"
      ],
      "otg_id": "GCST000835",
      "neg_log_pval": 71.69897000433602,
      "gwas_catalog_id": "GCST000835",
      "pubmed_id": "20953186"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31274414
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis [EA]",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=978",
        "European=1112"
      ],
      "otg_id": "GCST006575_2",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006575",
      "pubmed_id": "25604533"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (301152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 100.0,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=6880"
      ],
      "otg_id": "GCST003270",
      "neg_log_pval": 98.69897000433602,
      "gwas_catalog_id": "GCST003270",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=2759"
      ],
      "otg_id": "GCST000322",
      "neg_log_pval": 100.0,
      "gwas_catalog_id": "GCST000322",
      "pubmed_id": "19169254"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=1618"
      ],
      "otg_id": "GCST000836",
      "neg_log_pval": 31.397940008672037,
      "gwas_catalog_id": "GCST000836",
      "pubmed_id": "20953188"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=1618"
      ],
      "otg_id": "GCST000836",
      "neg_log_pval": 31.397940008672037,
      "gwas_catalog_id": "GCST000836",
      "pubmed_id": "20953188"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31285148
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=6880"
      ],
      "otg_id": "GCST003270",
      "neg_log_pval": 98.69897000433602,
      "gwas_catalog_id": "GCST003270",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31291060
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004208"
      ],
      "reported_trait_name": "Vitiligo",
      "standard_trait_name": "Vitiligo"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2546"
      ],
      "otg_id": "GCST000692",
      "neg_log_pval": 32.69897000433602,
      "gwas_catalog_id": "GCST000692",
      "pubmed_id": "20526339"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (284506bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31297975
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2198"
      ],
      "otg_id": "GCST007043",
      "neg_log_pval": 36.0,
      "gwas_catalog_id": "GCST007043",
      "pubmed_id": "30552173"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31297975
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2198"
      ],
      "otg_id": "GCST007043",
      "neg_log_pval": 36.0,
      "gwas_catalog_id": "GCST007043",
      "pubmed_id": "30552173"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31298313
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001494"
      ],
      "reported_trait_name": "Psoriasis vulgaris",
      "standard_trait_name": "psoriasis vulgaris"
    },
    "association_info": {
      "ancestry": [
        "European=8941"
      ],
      "otg_id": "GCST003268",
      "neg_log_pval": 311.69897000433605,
      "gwas_catalog_id": "GCST003268",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000232810 at this locus (277252bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31301916
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2644"
      ],
      "otg_id": "GCST003360",
      "neg_log_pval": 22.045757490560675,
      "gwas_catalog_id": "GCST003360",
      "pubmed_id": "26891255"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (273649bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 213.39794000867204,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=7353"
      ],
      "otg_id": "GCST000833",
      "neg_log_pval": 213.39794000867204,
      "gwas_catalog_id": "GCST000833",
      "pubmed_id": "20953190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Cutaneous psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=6297"
      ],
      "otg_id": "GCST003269",
      "neg_log_pval": 206.39794000867204,
      "gwas_catalog_id": "GCST003269",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=737"
      ],
      "otg_id": "GCST000173",
      "neg_log_pval": 38.69897000433602,
      "gwas_catalog_id": "GCST000173",
      "pubmed_id": "18369459"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=737"
      ],
      "otg_id": "GCST000173",
      "neg_log_pval": 38.69897000433602,
      "gwas_catalog_id": "GCST000173",
      "pubmed_id": "18369459"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31306778
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Cutaneous psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=6297"
      ],
      "otg_id": "GCST003269",
      "neg_log_pval": 206.39794000867204,
      "gwas_catalog_id": "GCST003269",
      "pubmed_id": "26626624"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31312441
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2569"
      ],
      "otg_id": "GCST006984",
      "neg_log_pval": 33.39794000867204,
      "gwas_catalog_id": "GCST006984",
      "pubmed_id": "30498034"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (263125bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31344549
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=606"
      ],
      "otg_id": "GCST000165",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST000165",
      "pubmed_id": "18364390"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31344549
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=606"
      ],
      "otg_id": "GCST000165",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST000165",
      "pubmed_id": "18364390"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31353490
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 19.096910013008056,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (222075bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31354352
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [Turkish]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "Other=1828",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=1176"
      ],
      "otg_id": "GCST007844_4",
      "neg_log_pval": 119.22184874961636,
      "gwas_catalog_id": "GCST007844",
      "pubmed_id": "30946743"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (221214bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31354420
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=157242"
      ],
      "otg_id": "GCST003987",
      "neg_log_pval": 16.0,
      "gwas_catalog_id": "GCST003987",
      "pubmed_id": "27182965"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31354420
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=341215"
      ],
      "otg_id": "GCST007798",
      "neg_log_pval": 59.69897000433602,
      "gwas_catalog_id": "GCST007798",
      "pubmed_id": "30929738"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31358156
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [Iranian]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "Other=1828",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=1176"
      ],
      "otg_id": "GCST007844_3",
      "neg_log_pval": 90.04575749056067,
      "gwas_catalog_id": "GCST007844",
      "pubmed_id": "30946743"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (217409bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31359924
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000289"
      ],
      "reported_trait_name": "Bipolar disorder [addtive]",
      "standard_trait_name": "bipolar disorder"
    },
    "association_info": {
      "ancestry": [
        "European=4806"
      ],
      "otg_id": "GCST000961",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST000961",
      "pubmed_id": "21254220"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000289 and targets the gene ENSG00000232810 at this locus (215641bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31368323
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=7193"
      ],
      "otg_id": "GCST000563",
      "neg_log_pval": 303.30102999566395,
      "gwas_catalog_id": "GCST000563",
      "pubmed_id": "20062062"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (207242bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31368641
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003780"
      ],
      "reported_trait_name": "Behcet's disease",
      "standard_trait_name": "Behcet's syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1098"
      ],
      "otg_id": "GCST001768",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001768",
      "pubmed_id": "23001997"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (206925bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31377139
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [EA]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=22647",
        "East Asian=3117"
      ],
      "otg_id": "GCST005529_3",
      "neg_log_pval": 100.0,
      "gwas_catalog_id": "GCST005529",
      "pubmed_id": "23749187"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (198427bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31380742
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease [conditional on rs2284174]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692_13",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31380742
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000341"
      ],
      "reported_trait_name": "Chronic obstructive pulmonary disease [conditional on rs2284174]",
      "standard_trait_name": "chronic obstructive pulmonary disease"
    },
    "association_info": {
      "ancestry": [
        "European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811"
      ],
      "otg_id": "GCST007692_13",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST007692",
      "pubmed_id": "30804561"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31383435
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis [Turkish]",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=978",
        "European=1112"
      ],
      "otg_id": "GCST006575_3",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST006575",
      "pubmed_id": "25604533"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (192130bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31385552
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-negative)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=7156"
      ],
      "otg_id": "GCST002357",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST002357",
      "pubmed_id": "24532677"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000226979",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (186502bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31385552
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-negative)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=7156"
      ],
      "otg_id": "GCST002357",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST002357",
      "pubmed_id": "24532677"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug PLACULUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31385552
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis (ACPA-negative)",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=7156"
      ],
      "otg_id": "GCST002357",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST002357",
      "pubmed_id": "24532677"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31386461
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=788",
        "European=659"
      ],
      "otg_id": "GCST006863",
      "neg_log_pval": 15.221848749616356,
      "gwas_catalog_id": "GCST006863",
      "pubmed_id": "23830517"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31386461
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis [EA]",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=978",
        "European=1112"
      ],
      "otg_id": "GCST006575_2",
      "neg_log_pval": 14.522878745280337,
      "gwas_catalog_id": "GCST006575",
      "pubmed_id": "25604533"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31392512
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Acute anterior uveitis in ankylosing spondylitis",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=2930"
      ],
      "otg_id": "GCST007361",
      "neg_log_pval": 17.30102999566398,
      "gwas_catalog_id": "GCST007361",
      "pubmed_id": "25200001"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (183053bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31396930
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 22.0,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31396930
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 22.0,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31398010
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003898"
      ],
      "reported_trait_name": "Ankylosing spondylitis [less than]",
      "standard_trait_name": "ankylosing spondylitis"
    },
    "association_info": {
      "ancestry": [
        "European=11802"
      ],
      "otg_id": "GCST001149_2",
      "neg_log_pval": 200.0,
      "gwas_catalog_id": "GCST001149",
      "pubmed_id": "21743469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (177556bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31440051
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004775"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "toxic epidermal necrolysis"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (135514bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31440051
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004276"
      ],
      "reported_trait_name": "Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN)",
      "standard_trait_name": "Stevens-Johnson syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=2305"
      ],
      "otg_id": "GCST001181",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST001181",
      "pubmed_id": "21801394"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (135514bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31464003
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=737"
      ],
      "otg_id": "GCST000173",
      "neg_log_pval": 25.69897000433602,
      "gwas_catalog_id": "GCST000173",
      "pubmed_id": "18369459"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31464003
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=737"
      ],
      "otg_id": "GCST000173",
      "neg_log_pval": 25.69897000433602,
      "gwas_catalog_id": "GCST000173",
      "pubmed_id": "18369459"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31466554
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 44.52287874528034,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (109011bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31466589
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003063"
      ],
      "reported_trait_name": "Polymyositis",
      "standard_trait_name": "polymyositis"
    },
    "association_info": {
      "ancestry": [
        "European=16582"
      ],
      "otg_id": "GCST006052",
      "neg_log_pval": 75.22184874961636,
      "gwas_catalog_id": "GCST006052",
      "pubmed_id": "26362759"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0003063 and targets the gene ENSG00000232810 at this locus (108976bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31466589
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 44.69897000433602,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108976bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31466844
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 44.69897000433602,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108721bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31475005
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 42.52287874528034,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (100560bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31481085
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "South Asian=1225"
      ],
      "otg_id": "GCST002453",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST002453",
      "pubmed_id": "24837172"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31481085
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "South Asian=1225"
      ],
      "otg_id": "GCST002453",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST002453",
      "pubmed_id": "24837172"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31481199
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 48.30102999566398,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (94366bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31481199
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [HDL]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=10564"
      ],
      "otg_id": "GCST001436_2",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001436",
      "pubmed_id": "22399527"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000195 and targets the gene ENSG00000232810 at this locus (94366bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31484059
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 49.0,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (91507bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31504943
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "African unspecified, African American or Afro-Caribbean=8204",
        "European=127669",
        "East Asian=5215",
        "Hispanic or Latin American=1398"
      ],
      "otg_id": "GCST005212",
      "neg_log_pval": 11.045757490560675,
      "gwas_catalog_id": "GCST005212",
      "pubmed_id": "29273806"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (70622bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31508681
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 47.39794000867204,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (66885bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31537703
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004276"
      ],
      "reported_trait_name": "Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)",
      "standard_trait_name": "Stevens-Johnson syndrome"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1005"
      ],
      "otg_id": "GCST001239",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001239",
      "pubmed_id": "21912425"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (37863bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31537703
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 48.52287874528034,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (37863bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31537703
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004775"
      ],
      "reported_trait_name": "Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)",
      "standard_trait_name": "toxic epidermal necrolysis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=1005"
      ],
      "otg_id": "GCST001239",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001239",
      "pubmed_id": "21912425"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (37863bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31546470
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000783"
      ],
      "reported_trait_name": "Myositis",
      "standard_trait_name": "myositis"
    },
    "association_info": {
      "ancestry": [
        "European=6434"
      ],
      "otg_id": "GCST003092",
      "neg_log_pval": 48.221848749616356,
      "gwas_catalog_id": "GCST003092",
      "pubmed_id": "26291516"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (29095bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31574531
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=21389"
      ],
      "otg_id": "GCST000879",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST000879",
      "pubmed_id": "21102463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (1034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31600692
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 22.69897000433602,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31600692
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 22.69897000433602,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31602893
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_1001857"
      ],
      "reported_trait_name": "Takayasu arteritis [Turkish]",
      "standard_trait_name": "Takayasu arteritis"
    },
    "association_info": {
      "ancestry": [
        "Other=978",
        "European=1112"
      ],
      "otg_id": "GCST006575_3",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006575",
      "pubmed_id": "25604533"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (24557bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31648589
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=69395"
      ],
      "otg_id": "GCST001238",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST001238",
      "pubmed_id": "21909115"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (70254bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31654829
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=700"
      ],
      "otg_id": "GCST001203",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST001203",
      "pubmed_id": "21844665"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug OZORALIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31654829
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=700"
      ],
      "otg_id": "GCST001203",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST001203",
      "pubmed_id": "21844665"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000226979",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (80506bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31654829
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=700"
      ],
      "otg_id": "GCST001203",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST001203",
      "pubmed_id": "21844665"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31753256
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=3037"
      ],
      "otg_id": "GCST000142",
      "neg_log_pval": 51.69897000433602,
      "gwas_catalog_id": "GCST000142",
      "pubmed_id": "18204446"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (174921bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31766173
      },
      "alleles": {
        "reference": "CAG",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Poor prognosis in Crohn's disease",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=2734"
      ],
      "otg_id": "GCST004053",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST004053",
      "pubmed_id": "28067912"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (187838bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31781365
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_797"
      ],
      "reported_trait_name": "Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)",
      "standard_trait_name": "Sarcoidosis"
    },
    "association_info": {
      "ancestry": [
        "European=1048"
      ],
      "otg_id": "GCST005541",
      "neg_log_pval": 31.397940008672037,
      "gwas_catalog_id": "GCST005541",
      "pubmed_id": "26651848"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31781365
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "Orphanet_797"
      ],
      "reported_trait_name": "Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome)",
      "standard_trait_name": "Sarcoidosis"
    },
    "association_info": {
      "ancestry": [
        "European=1048"
      ],
      "otg_id": "GCST005541",
      "neg_log_pval": 31.397940008672037,
      "gwas_catalog_id": "GCST005541",
      "pubmed_id": "26651848"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31819390
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 19.30102999566398,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (241055bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31858928
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 18.154901959985743,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (280592bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31869289
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004208"
      ],
      "reported_trait_name": "Vitiligo",
      "standard_trait_name": "Vitiligo"
    },
    "association_info": {
      "ancestry": [
        "East Asian=2546"
      ],
      "otg_id": "GCST000692",
      "neg_log_pval": 48.0,
      "gwas_catalog_id": "GCST000692",
      "pubmed_id": "20526339"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (290954bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31902549
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=3163"
      ],
      "otg_id": "GCST002463",
      "neg_log_pval": 20.096910013008056,
      "gwas_catalog_id": "GCST002463",
      "pubmed_id": "24871463"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (324214bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31913532
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 15.698970004336019,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (335197bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31916180
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=3105"
      ],
      "otg_id": "GCST004873",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004873",
      "pubmed_id": "28881265"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001065 and targets the gene ENSG00000232810 at this locus (337844bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31949763
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "South Asian=1225"
      ],
      "otg_id": "GCST002453",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST002453",
      "pubmed_id": "24837172"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31949763
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "South Asian=1225"
      ],
      "otg_id": "GCST002453",
      "neg_log_pval": 13.301029995663981,
      "gwas_catalog_id": "GCST002453",
      "pubmed_id": "24837172"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31951083
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 24.30102999566398,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31951083
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001359"
      ],
      "reported_trait_name": "Type 1 diabetes and autoimmune thyroid diseases",
      "standard_trait_name": "insulin-dependent diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=1073"
      ],
      "otg_id": "GCST002876",
      "neg_log_pval": 24.30102999566398,
      "gwas_catalog_id": "GCST002876",
      "pubmed_id": "25936594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31968280
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2198"
      ],
      "otg_id": "GCST007043",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007043",
      "pubmed_id": "30552173"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31968280
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003778"
      ],
      "reported_trait_name": "Psoriatic arthritis",
      "standard_trait_name": "psoriatic arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=2198"
      ],
      "otg_id": "GCST007043",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007043",
      "pubmed_id": "30552173"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31979683
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (401348bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 31979683
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Broad depression or schizophrenia",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=150064",
        "European=70017"
      ],
      "otg_id": "GCST007257",
      "neg_log_pval": 12.0,
      "gwas_catalog_id": "GCST007257",
      "pubmed_id": "30626913"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (401348bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 32061428
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus [EA]",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5057",
        "European=10995"
      ],
      "otg_id": "GCST003622_3",
      "neg_log_pval": 100.69897000433602,
      "gwas_catalog_id": "GCST003622",
      "pubmed_id": "27399966"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (483092bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 32070773
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=18264",
        "African American or Afro-Caribbean=5422",
        "Hispanic or Latin American=3888"
      ],
      "otg_id": "GCST005752",
      "neg_log_pval": 116.22184874961636,
      "gwas_catalog_id": "GCST005752",
      "pubmed_id": "28714469"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (492437bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 32077074
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "East Asian=9469"
      ],
      "otg_id": "GCST002627",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST002627",
      "pubmed_id": "25249183"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000232810",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (498738bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 36387877
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959_3",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112062",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 36387877
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112062",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "AAAAG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "AAAAG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "AG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39071364
      },
      "alleles": {
        "reference": "A",
        "alternative": "AG"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39156672
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000112164 at this locus (65370bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39166323
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (75021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39207146
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 11.117418546445549,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39207146
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39314595
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug LIXISENATIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39314595
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39316274
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=15000",
        "South East Asian=2034",
        "Asian unspecified=1783"
      ],
      "otg_id": "GCST001351",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001351",
      "pubmed_id": "22158537"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 39316274
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=15000",
        "South East Asian=2034",
        "Asian unspecified=1783"
      ],
      "otg_id": "GCST001351",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST001351",
      "pubmed_id": "22158537"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112164",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Glucagon-like peptide 1 receptor agonist drug LIRAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43726861
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000112715 at this locus (43324bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43791136
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 11.39848321634999,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43791136
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43791136
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 8.3767507096021,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Advanced age-related macular degeneration [EA]",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=33976"
      ],
      "otg_id": "GCST003219_2",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST003219",
      "pubmed_id": "26691988"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Age-related macular degeneration",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=55115",
        "South Asian=229",
        "East Asian=4150"
      ],
      "otg_id": "GCST001884",
      "neg_log_pval": 15.045757490560675,
      "gwas_catalog_id": "GCST001884",
      "pubmed_id": "23455636"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004683"
      ],
      "reported_trait_name": "Advanced age-related macular degeneration [EA]",
      "standard_trait_name": "wet macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=33976"
      ],
      "otg_id": "GCST003219_2",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST003219",
      "pubmed_id": "26691988"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004683"
      ],
      "reported_trait_name": "Advanced age-related macular degeneration [EA]",
      "standard_trait_name": "wet macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=33976"
      ],
      "otg_id": "GCST003219_2",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST003219",
      "pubmed_id": "26691988"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Advanced age-related macular degeneration [EA]",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=33976"
      ],
      "otg_id": "GCST003219_2",
      "neg_log_pval": 14.0,
      "gwas_catalog_id": "GCST003219",
      "pubmed_id": "26691988"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43858890
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Age-related macular degeneration",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=55115",
        "South Asian=229",
        "East Asian=4150"
      ],
      "otg_id": "GCST001884",
      "neg_log_pval": 15.045757490560675,
      "gwas_catalog_id": "GCST001884",
      "pubmed_id": "23455636"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43860845
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Age-related macular degeneration",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=6728"
      ],
      "otg_id": "GCST001100",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST001100",
      "pubmed_id": "21665990"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 43860845
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001365"
      ],
      "reported_trait_name": "Age-related macular degeneration",
      "standard_trait_name": "age-related macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "European=6728"
      ],
      "otg_id": "GCST001100",
      "neg_log_pval": 8.045757490560675,
      "gwas_catalog_id": "GCST001100",
      "pubmed_id": "21665990"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug CONBERCEPT is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44003090
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004683"
      ],
      "reported_trait_name": "Exudative age-related macular degeneration",
      "standard_trait_name": "wet macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7810"
      ],
      "otg_id": "GCST002766",
      "neg_log_pval": 17.221848749616356,
      "gwas_catalog_id": "GCST002766",
      "pubmed_id": "25629512"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44003090
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004683"
      ],
      "reported_trait_name": "Exudative age-related macular degeneration",
      "standard_trait_name": "wet macular degeneration"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7810"
      ],
      "otg_id": "GCST002766",
      "neg_log_pval": 17.221848749616356,
      "gwas_catalog_id": "GCST002766",
      "pubmed_id": "25629512"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112715",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Vascular endothelial growth factor A inhibitor drug AFLIBERCEPT is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44265183
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5683"
      ],
      "otg_id": "GCST001681",
      "neg_log_pval": 15.0,
      "gwas_catalog_id": "GCST001681",
      "pubmed_id": "23028356"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44265183
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "East Asian=20965"
      ],
      "otg_id": "GCST001454",
      "neg_log_pval": 18.221848749616356,
      "gwas_catalog_id": "GCST001454",
      "pubmed_id": "22446963"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959_3",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959",
      "neg_log_pval": 18.69897000433602,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [East Asian]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_3",
      "neg_log_pval": 12.698970004336019,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [EA]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "European=58284",
        "East Asian=22515"
      ],
      "otg_id": "GCST002318_2",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST002318",
      "pubmed_id": "24390342"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44266184
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000685"
      ],
      "reported_trait_name": "Rheumatoid arthritis [East Asian]",
      "standard_trait_name": "rheumatoid arthritis"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2308"
      ],
      "otg_id": "GCST006959_4",
      "neg_log_pval": 12.045757490560675,
      "gwas_catalog_id": "GCST006959",
      "pubmed_id": "30423114"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 44626422
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Stroke (ischemic) [LAA]",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "European=2406"
      ],
      "otg_id": "GCST001659",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST001659",
      "pubmed_id": "22941190"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112759",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000112759 at this locus (392271bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 46709361
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005672"
      ],
      "reported_trait_name": "Lipoprotein phospholipase A2 activity in cardiovascular disease",
      "standard_trait_name": "acute coronary syndrome"
    },
    "association_info": {
      "ancestry": [
        "European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=22156"
      ],
      "otg_id": "GCST004963",
      "neg_log_pval": 178.0,
      "gwas_catalog_id": "GCST004963",
      "pubmed_id": "28753643"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146070",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 46709361
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005672"
      ],
      "reported_trait_name": "Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease",
      "standard_trait_name": "acute coronary syndrome"
    },
    "association_info": {
      "ancestry": [
        "European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=10874"
      ],
      "otg_id": "GCST004966",
      "neg_log_pval": 46.096910013008056,
      "gwas_catalog_id": "GCST004966",
      "pubmed_id": "28753643"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146070",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 52427338
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000274"
      ],
      "reported_trait_name": "Atopic march",
      "standard_trait_name": "atopic eczema"
    },
    "association_info": {
      "ancestry": [
        "European=11181"
      ],
      "otg_id": "GCST003180",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST003180",
      "pubmed_id": "26542096"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112115",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin 17A inhibitor drug SECUKINUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000112115 at this locus (236700bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151494876
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151494876
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151589269
      },
      "alleles": {
        "reference": "AAC",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000537"
      ],
      "reported_trait_name": "Hypertension | non-cancer illness code, self-reported",
      "standard_trait_name": "hypertension"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1065",
      "neg_log_pval": 8.287247628480976,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000091831 at this locus (67422bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151592978
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 20.69897000433602,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151592978
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 20.69897000433602,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151592978
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=22627"
      ],
      "otg_id": "GCST001937",
      "neg_log_pval": 20.69897000433602,
      "gwas_catalog_id": "GCST001937",
      "pubmed_id": "23535729"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 26.154901959985743,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 26.154901959985743,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 26.154901959985743,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151597721
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 19.0,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151604372
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151604372
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=688809"
      ],
      "otg_id": "GCST006477",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST006477",
      "pubmed_id": "29942085"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151621059
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=15566"
      ],
      "otg_id": "GCST005075",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST005075",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151621059
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=15566"
      ],
      "otg_id": "GCST005075",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST005075",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151621059
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=15566"
      ],
      "otg_id": "GCST005075",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST005075",
      "pubmed_id": "29058716"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151625017
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 27.397940008672037,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151625017
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 27.397940008672037,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151625017
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=19291"
      ],
      "otg_id": "GCST003845",
      "neg_log_pval": 27.397940008672037,
      "gwas_catalog_id": "GCST003845",
      "pubmed_id": "27117709"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=39387"
      ],
      "otg_id": "GCST001930",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST001930",
      "pubmed_id": "23535733"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=39387"
      ],
      "otg_id": "GCST001930",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST001930",
      "pubmed_id": "23535733"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 14.154901959985743,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 14.154901959985743,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=13905"
      ],
      "otg_id": "GCST003520",
      "neg_log_pval": 14.154901959985743,
      "gwas_catalog_id": "GCST003520",
      "pubmed_id": "27354352"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 23.221848749616356,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=2727"
      ],
      "otg_id": "GCST001916",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001916",
      "pubmed_id": "23544013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=39387"
      ],
      "otg_id": "GCST001930",
      "neg_log_pval": 15.301029995663981,
      "gwas_catalog_id": "GCST001930",
      "pubmed_id": "23535733"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 23.221848749616356,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=33864"
      ],
      "otg_id": "GCST004950",
      "neg_log_pval": 23.221848749616356,
      "gwas_catalog_id": "GCST004950",
      "pubmed_id": "25751625"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=3027"
      ],
      "otg_id": "GCST000343",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST000343",
      "pubmed_id": "19219042"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=3027"
      ],
      "otg_id": "GCST000343",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST000343",
      "pubmed_id": "19219042"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "East Asian=3027"
      ],
      "otg_id": "GCST000343",
      "neg_log_pval": 14.698970004336019,
      "gwas_catalog_id": "GCST000343",
      "pubmed_id": "19219042"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=2727"
      ],
      "otg_id": "GCST001916",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001916",
      "pubmed_id": "23544013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151627231
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast Cancer in BRCA1 mutation carriers",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=2727"
      ],
      "otg_id": "GCST001916",
      "neg_log_pval": 8.301029995663981,
      "gwas_catalog_id": "GCST001916",
      "pubmed_id": "23544013"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151628671
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 15.344861565188618,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151628671
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 15.344861565188618,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151628671
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 15.344861565188618,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631197
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer | illnesses of mother",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=330828"
      ],
      "otg_id": "NEALE2_20110_5",
      "neg_log_pval": 12.785156151952302,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631197
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer | illnesses of mother",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=330828"
      ],
      "otg_id": "NEALE2_20110_5",
      "neg_log_pval": 12.785156151952302,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631197
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer | illnesses of mother",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=330828"
      ],
      "otg_id": "NEALE2_20110_5",
      "neg_log_pval": 12.785156151952302,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631510
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 7.895171596346344,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631510
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 7.895171596346344,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151631510
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 7.895171596346344,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151633699
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "Hispanic or Latin American=4710"
      ],
      "otg_id": "GCST002662",
      "neg_log_pval": 17.045757490560675,
      "gwas_catalog_id": "GCST002662",
      "pubmed_id": "25327703"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151633699
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "Hispanic or Latin American=4710"
      ],
      "otg_id": "GCST002662",
      "neg_log_pval": 17.045757490560675,
      "gwas_catalog_id": "GCST002662",
      "pubmed_id": "25327703"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151633699
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "Hispanic or Latin American=4710"
      ],
      "otg_id": "GCST002662",
      "neg_log_pval": 17.045757490560675,
      "gwas_catalog_id": "GCST002662",
      "pubmed_id": "25327703"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151634779
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 53.54668165995296,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151634779
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 53.54668165995296,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151634779
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 53.54668165995296,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151666222
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=32530",
        "African American or Afro-Caribbean=3748"
      ],
      "otg_id": "GCST001683",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001683",
      "pubmed_id": "22976474"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151666222
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=32530",
        "African American or Afro-Caribbean=3748"
      ],
      "otg_id": "GCST001683",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001683",
      "pubmed_id": "22976474"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151666222
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=32530",
        "African American or Afro-Caribbean=3748"
      ],
      "otg_id": "GCST001683",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST001683",
      "pubmed_id": "22976474"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151699255
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 18.080451241031152,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151699255
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 18.080451241031152,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151699255
      },
      "alleles": {
        "reference": "A",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 18.080451241031152,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151713685
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 7.47755576649368,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151713685
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 7.47755576649368,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 151713685
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 7.47755576649368,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152111767
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 25.84893674664625,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152111767
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 25.84893674664625,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152111767
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 25.84893674664625,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152115881
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 12.767003889607846,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152115881
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 12.767003889607846,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152115881
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=401447"
      ],
      "otg_id": "SAIGE_174",
      "neg_log_pval": 12.767003889607846,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152232879
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152232879
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152232879
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis [EA]",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549_2",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152232879
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001065"
      ],
      "reported_trait_name": "Endometriosis [EA]",
      "standard_trait_name": "endometriosis"
    },
    "association_info": {
      "ancestry": [
        "European=204641",
        "East Asian=4262"
      ],
      "otg_id": "GCST004549_2",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004549",
      "pubmed_id": "28537267"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152241136
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000731"
      ],
      "reported_trait_name": "Uterine fibroids",
      "standard_trait_name": "uterine fibroid"
    },
    "association_info": {
      "ancestry": [
        "European=539925"
      ],
      "otg_id": "GCST006462",
      "neg_log_pval": 23.045757490560675,
      "gwas_catalog_id": "GCST006462",
      "pubmed_id": "30194396"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000731 and targets the gene ENSG00000091831 at this locus (111518bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152393471
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000289"
      ],
      "reported_trait_name": "Bipolar disorder",
      "standard_trait_name": "bipolar disorder"
    },
    "association_info": {
      "ancestry": [
        "European=33181"
      ],
      "otg_id": "GCST003962",
      "neg_log_pval": 7.3979400086720375,
      "gwas_catalog_id": "GCST003962",
      "pubmed_id": "28072414"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (263852bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152469438
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=61220"
      ],
      "otg_id": "GCST001877_3",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001877",
      "pubmed_id": "23453885"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000091831 at this locus (339820bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152469438
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000289"
      ],
      "reported_trait_name": "Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]",
      "standard_trait_name": "bipolar disorder"
    },
    "association_info": {
      "ancestry": [
        "European=61220"
      ],
      "otg_id": "GCST001877_3",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001877",
      "pubmed_id": "23453885"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (339820bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152469438
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=61220"
      ],
      "otg_id": "GCST001877_3",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001877",
      "pubmed_id": "23453885"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 152469438
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis]",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=61220"
      ],
      "otg_id": "GCST001877_3",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST001877",
      "pubmed_id": "23453885"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000091831",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 153704004
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005611"
      ],
      "reported_trait_name": "Methadone dose in opioid dependence [AA]",
      "standard_trait_name": "opioid dependence"
    },
    "association_info": {
      "ancestry": [
        "European=1027",
        "African American or Afro-Caribbean=383"
      ],
      "otg_id": "GCST004136",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004136",
      "pubmed_id": "28115739"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112038",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mu opioid receptor agonist drug MORPHINE is Phase IV for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 153704004
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005611"
      ],
      "reported_trait_name": "Methadone dose in opioid dependence [AA]",
      "standard_trait_name": "opioid dependence"
    },
    "association_info": {
      "ancestry": [
        "European=1027",
        "African American or Afro-Caribbean=383"
      ],
      "otg_id": "GCST004136",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004136",
      "pubmed_id": "28115739"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112038",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mu opioid receptor agonist drug TRAMADOL is Phase III for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 153704004
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005611"
      ],
      "reported_trait_name": "Methadone dose in opioid dependence [AA]",
      "standard_trait_name": "opioid dependence"
    },
    "association_info": {
      "ancestry": [
        "European=1027",
        "African American or Afro-Caribbean=383"
      ],
      "otg_id": "GCST004136",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004136",
      "pubmed_id": "28115739"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000112038",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Mu opioid receptor antagonist drug NALDEMEDINE is Phase II for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160330499
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 88.32422165832591,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (371740bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 30.522878745280337,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 19.416801226031378,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 11.869666231504993,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 11.869666231504993,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 31.75870261289001,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160490564
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 28.657577319177793,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160576086
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease in diabetes",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=15666"
      ],
      "otg_id": "GCST006405",
      "neg_log_pval": 11.522878745280337,
      "gwas_catalog_id": "GCST006405",
      "pubmed_id": "30003307"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (126153bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack/myocardial infarction | non-cancer illness code, self-reported",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1075",
      "neg_log_pval": 28.71524000401907,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 153.0096611452124,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 61.367542707815275,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack/myocardial infarction | non-cancer illness code, self-reported",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1075",
      "neg_log_pval": 28.71524000401907,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 40.28149831113272,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 119.20065945054642,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 40.28149831113272,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 153.52287874528034,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160584578
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 38.30102999566398,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160585045
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160585045
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 10.522878745280337,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 26.045757490560675,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 26.045757490560675,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=63731"
      ],
      "otg_id": "GCST004787",
      "neg_log_pval": 48.69897000433602,
      "gwas_catalog_id": "GCST004787",
      "pubmed_id": "28714975"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Coronary artery disease or ischemic stroke",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "NR=123388"
      ],
      "otg_id": "GCST002287",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002287",
      "pubmed_id": "24262325"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack | vascular/heart problems diagnosed by doctor",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=360420"
      ],
      "otg_id": "NEALE2_6150_1",
      "neg_log_pval": 27.967377210462196,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack | vascular/heart problems diagnosed by doctor",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=360420"
      ],
      "otg_id": "NEALE2_6150_1",
      "neg_log_pval": 27.967377210462196,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Coronary artery disease or ischemic stroke",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "NR=123388"
      ],
      "otg_id": "GCST002287",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002287",
      "pubmed_id": "24262325"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug RETEPLASE is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160589086
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000712"
      ],
      "reported_trait_name": "Coronary artery disease or ischemic stroke",
      "standard_trait_name": "cerebrovascular accident"
    },
    "association_info": {
      "ancestry": [
        "NR=123388"
      ],
      "otg_id": "GCST002287",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST002287",
      "pubmed_id": "24262325"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug DESMOTEPLASE is Phase III for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=547261"
      ],
      "otg_id": "GCST005195",
      "neg_log_pval": 76.85387196432177,
      "gwas_catalog_id": "GCST005195",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 25.059981844992336,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack/myocardial infarction | non-cancer illness code, self-reported",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1075",
      "neg_log_pval": 17.90926593057954,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack/myocardial infarction | non-cancer illness code, self-reported",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1075",
      "neg_log_pval": 17.90926593057954,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Ischemic heart disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=408458"
      ],
      "otg_id": "SAIGE_411",
      "neg_log_pval": 42.36957212497498,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160591981
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=388806"
      ],
      "otg_id": "SAIGE_411_2",
      "neg_log_pval": 25.059981844992336,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160596331
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 9.409046764812015,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (105907bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160666831
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (35407bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160687112
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 23.69897000433602,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160687112
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Myocardial infarction",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "African American or Afro-Caribbean=2908",
        "Hispanic or Latin American=3615",
        "South Asian=23156",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=754",
        "East Asian=9396",
        "European=126630"
      ],
      "otg_id": "GCST003117",
      "neg_log_pval": 23.69897000433602,
      "gwas_catalog_id": "GCST003117",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160690668
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack | vascular/heart problems diagnosed by doctor",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=360420"
      ],
      "otg_id": "NEALE2_6150_1",
      "neg_log_pval": 17.657683931817257,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160690668
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000612"
      ],
      "reported_trait_name": "Heart attack | vascular/heart problems diagnosed by doctor",
      "standard_trait_name": "myocardial infarction"
    },
    "association_info": {
      "ancestry": [
        "European=360420"
      ],
      "otg_id": "NEALE2_6150_1",
      "neg_log_pval": 17.657683931817257,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160690668
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=250736"
      ],
      "otg_id": "GCST005196",
      "neg_log_pval": 91.30102999566398,
      "gwas_catalog_id": "GCST005196",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160690668
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 96.70114692359029,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "6",
        "position": 160702419
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European=141217",
        "African American or Afro-Caribbean=3139",
        "Hispanic or Latin American=4095",
        "South Asian=25557",
        "Greater Middle Eastern (Middle Eastern / North African / Persian)=2268",
        "East Asian=11323"
      ],
      "otg_id": "GCST003116",
      "neg_log_pval": 31.69897000433602,
      "gwas_catalog_id": "GCST003116",
      "pubmed_id": "26343387"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000122194",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 22743871
      },
      "alleles": {
        "reference": "AT",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | non-cancer illness code, self-reported",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1111",
      "neg_log_pval": 8.507692295087963,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000136244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 22743871
      },
      "alleles": {
        "reference": "AT",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=360527"
      ],
      "otg_id": "NEALE2_6152_8",
      "neg_log_pval": 9.229103089046006,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000136244",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44135258
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=191764"
      ],
      "otg_id": "GCST007847",
      "neg_log_pval": 11.301029995663981,
      "gwas_catalog_id": "GCST007847",
      "pubmed_id": "30718926"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (377278bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44176538
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease and triglyceride levels (multivariate analysis)",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "European, NR=735838"
      ],
      "otg_id": "GCST007545",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST007545",
      "pubmed_id": "30525989"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (335997bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44189469
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Glycemic traits [2-hPG]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7696"
      ],
      "otg_id": "GCST001965_2",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST001965",
      "pubmed_id": "23575436"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44189469
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Glycemic traits [FPG]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7696"
      ],
      "otg_id": "GCST001965_3",
      "neg_log_pval": 17.30102999566398,
      "gwas_catalog_id": "GCST001965",
      "pubmed_id": "23575436"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44189469
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Glycemic traits [1-hPG]",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=7696"
      ],
      "otg_id": "GCST001965",
      "neg_log_pval": 8.522878745280337,
      "gwas_catalog_id": "GCST001965",
      "pubmed_id": "23575436"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44191617
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [GLU]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=10564"
      ],
      "otg_id": "GCST001436",
      "neg_log_pval": 12.397940008672037,
      "gwas_catalog_id": "GCST001436",
      "pubmed_id": "22399527"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (320918bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44209229
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001360"
      ],
      "reported_trait_name": "Type 2 diabetes",
      "standard_trait_name": "type II diabetes mellitus"
    },
    "association_info": {
      "ancestry": [
        "European=655666",
        "South Asian=3650"
      ],
      "otg_id": "GCST006867",
      "neg_log_pval": 8.397940008672037,
      "gwas_catalog_id": "GCST006867",
      "pubmed_id": "30054458"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (303306bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44220272
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [GLU]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=10564"
      ],
      "otg_id": "GCST001436",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST001436",
      "pubmed_id": "22399527"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44220272
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000195"
      ],
      "reported_trait_name": "Metabolic syndrome [GLU]",
      "standard_trait_name": "metabolic syndrome"
    },
    "association_info": {
      "ancestry": [
        "European=10564"
      ],
      "otg_id": "GCST001436",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST001436",
      "pubmed_id": "22399527"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44542387
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000015520 at this locus (1072bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44542387
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 7.301029995663981,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196262",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196262 at this locus (254293bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44544952
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 14.154901959985743,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000015520 at this locus (3637bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 44572630
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Ulcerative colitis",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=26405"
      ],
      "otg_id": "GCST000964",
      "neg_log_pval": 9.097453220686008,
      "gwas_catalog_id": "GCST000964",
      "pubmed_id": "21297633"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000196262",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000196262 at this locus (224051bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 45038379
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000378"
      ],
      "reported_trait_name": "Coronary artery disease",
      "standard_trait_name": "coronary artery disease"
    },
    "association_info": {
      "ancestry": [
        "NR=296525"
      ],
      "otg_id": "GCST005194",
      "neg_log_pval": 7.438898616350944,
      "gwas_catalog_id": "GCST005194",
      "pubmed_id": "29212778"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000015520",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (497064bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Below median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_2",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 33.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Below median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_2",
      "neg_log_pval": 11.154901959985743,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=9218"
      ],
      "otg_id": "GCST003220",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST003220",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 33.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_3",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 33.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Non-glioblastoma glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24009"
      ],
      "otg_id": "GCST004348",
      "neg_log_pval": 7.698970004336019,
      "gwas_catalog_id": "GCST004348",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 15.397940008672037,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_3",
      "neg_log_pval": 11.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=11582"
      ],
      "otg_id": "GCST003228",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST003228",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=30659"
      ],
      "otg_id": "GCST004347",
      "neg_log_pval": 26.397940008672037,
      "gwas_catalog_id": "GCST004347",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 54848587
      },
      "alleles": {
        "reference": "T",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=9218"
      ],
      "otg_id": "GCST003220",
      "neg_log_pval": 10.221848749616356,
      "gwas_catalog_id": "GCST003220",
      "pubmed_id": "26424050"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_3",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 22.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 22.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 10.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000326"
      ],
      "reported_trait_name": "Glioblastoma",
      "standard_trait_name": "central nervous system cancer"
    },
    "association_info": {
      "ancestry": [
        "European=24381"
      ],
      "otg_id": "GCST004349",
      "neg_log_pval": 22.30102999566398,
      "gwas_catalog_id": "GCST004349",
      "pubmed_id": "28346443"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55067179
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480_3",
      "neg_log_pval": 8.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55091656
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 55091656
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000519"
      ],
      "reported_trait_name": "Glioblastoma (age-stratified) [Above median age-at-diagnosis]",
      "standard_trait_name": "glioblastoma multiforme"
    },
    "association_info": {
      "ancestry": [
        "NR=15094"
      ],
      "otg_id": "GCST006480",
      "neg_log_pval": 9.698970004336019,
      "gwas_catalog_id": "GCST006480",
      "pubmed_id": "30152087"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000146648",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 82825088
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Depression",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "NR=361315",
        "European=446238"
      ],
      "otg_id": "GCST007342",
      "neg_log_pval": 13.045757490560675,
      "gwas_catalog_id": "GCST007342",
      "pubmed_id": "30718901"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000153956",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (381311bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 82839058
      },
      "alleles": {
        "reference": "A",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Major depressive disorder",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=6507"
      ],
      "otg_id": "GCST004486",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004486",
      "pubmed_id": "28540843"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000153956",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 82839058
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003761"
      ],
      "reported_trait_name": "Major depressive disorder",
      "standard_trait_name": "unipolar depression"
    },
    "association_info": {
      "ancestry": [
        "European=6507"
      ],
      "otg_id": "GCST004486",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST004486",
      "pubmed_id": "28540843"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000153956",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "Other=1097",
        "NR=150064"
      ],
      "otg_id": "GCST003048",
      "neg_log_pval": 10.154901959985743,
      "gwas_catalog_id": "GCST003048",
      "pubmed_id": "26198764"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 9.397940008672037,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia [EA]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201_2",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=105318"
      ],
      "otg_id": "GCST006803",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST006803",
      "pubmed_id": "29483656"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=82315",
        "East Asian=5219"
      ],
      "otg_id": "GCST002539",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST002539",
      "pubmed_id": "25056061"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Autism spectrum disorder or schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "European=13574",
        "NR=2380"
      ],
      "otg_id": "GCST004521",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST004521",
      "pubmed_id": "28540026"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 86798310
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=26026",
        "European=82315"
      ],
      "otg_id": "GCST004946",
      "neg_log_pval": 9.522878745280337,
      "gwas_catalog_id": "GCST004946",
      "pubmed_id": "28991256"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 87170125
      },
      "alleles": {
        "reference": "T",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Schizophrenia",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "East Asian=45528"
      ],
      "otg_id": "GCST007201",
      "neg_log_pval": 7.522878745280337,
      "gwas_catalog_id": "GCST007201",
      "pubmed_id": "30285260"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000198822",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (305241bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100689872
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (200123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100689872
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005411"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizoaffective disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100689872
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000289"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "bipolar disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (200123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100689872
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005411"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizoaffective disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100701361
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005411"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizoaffective disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100701361
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000692"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizophrenia"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (188633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100701361
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000289"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "bipolar disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (188633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 100701361
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0005411"
      ],
      "reported_trait_name": "Pursuit maintenance gain in psychotic disorders [African]",
      "standard_trait_name": "schizoaffective disorder"
    },
    "association_info": {
      "ancestry": [
        "African unspecified=224",
        "European=367"
      ],
      "otg_id": "GCST005028_2",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST005028",
      "pubmed_id": "29064472"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000087085",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 140242504
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000305"
      ],
      "reported_trait_name": "Breast cancer",
      "standard_trait_name": "breast carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=139274"
      ],
      "otg_id": "GCST004988",
      "neg_log_pval": 15.979638717352293,
      "gwas_catalog_id": "GCST004988",
      "pubmed_id": "29059683"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000157764",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Serine/threonine-protein kinase B-raf inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000157764 at this locus (476824bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 10.674484336636851,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061",
      "neg_log_pval": 9.154901959985743,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=1030836"
      ],
      "otg_id": "GCST006414",
      "neg_log_pval": 10.674484336636851,
      "gwas_catalog_id": "GCST006414",
      "pubmed_id": "30061737"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150964321
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000275"
      ],
      "reported_trait_name": "Atrial fibrillation [EA]",
      "standard_trait_name": "atrial fibrillation"
    },
    "association_info": {
      "ancestry": [
        "European=537409",
        "East Asian=36792",
        "African American or Afro-Caribbean=8967",
        "Hispanic or Latin American=5022"
      ],
      "otg_id": "GCST006061_3",
      "neg_log_pval": 10.045757490560675,
      "gwas_catalog_id": "GCST006061",
      "pubmed_id": "29892015"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 150993088
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000319"
      ],
      "reported_trait_name": "Cardiovascular disease",
      "standard_trait_name": "cardiovascular system disease"
    },
    "association_info": {
      "ancestry": [
        "European=459000"
      ],
      "otg_id": "GCST007072",
      "neg_log_pval": 48.69897000433602,
      "gwas_catalog_id": "GCST007072",
      "pubmed_id": "30595370"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000055118",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "HERG blocker drug SOTALOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000055118 at this locus (14774bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "7",
        "position": 151253854
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001378"
      ],
      "reported_trait_name": "Multiple myeloma",
      "standard_trait_name": "multiple myeloma"
    },
    "association_info": {
      "ancestry": [
        "European=241704"
      ],
      "otg_id": "GCST004483",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST004483",
      "pubmed_id": "27363682"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000164885",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Cyclin-dependent kinase 5 inhibitor drug DINACICLIB is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000164885 at this locus (195958bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 4971927
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Psoriasis",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=33394"
      ],
      "otg_id": "GCST005527",
      "neg_log_pval": 7.481235531320022,
      "gwas_catalog_id": "GCST005527",
      "pubmed_id": "23143594"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (12463bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 4981602
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000676"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "psoriasis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 42.30102999566398,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (2788bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 4984530
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5057",
        "European=10995"
      ],
      "otg_id": "GCST003622",
      "neg_log_pval": 16.69897000433602,
      "gwas_catalog_id": "GCST003622",
      "pubmed_id": "27399966"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 4984530
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Systemic lupus erythematosus [Chinese]",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "East Asian=5057",
        "European=10995"
      ],
      "otg_id": "GCST003622_2",
      "neg_log_pval": 13.397940008672037,
      "gwas_catalog_id": "GCST003622",
      "pubmed_id": "27399966"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5049092
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002429"
      ],
      "reported_trait_name": "Polycythemia vera",
      "standard_trait_name": "polycythemia vera"
    },
    "association_info": {
      "ancestry": [
        "European=401535"
      ],
      "otg_id": "SAIGE_200_1",
      "neg_log_pval": 16.707743928643524,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5049092
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002429"
      ],
      "reported_trait_name": "Polycythemia vera",
      "standard_trait_name": "polycythemia vera"
    },
    "association_info": {
      "ancestry": [
        "European=401535"
      ],
      "otg_id": "SAIGE_200_1",
      "neg_log_pval": 16.707743928643524,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5049092
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002429"
      ],
      "reported_trait_name": "Polycythaemia vera | non-cancer illness code, self-reported",
      "standard_trait_name": "polycythemia vera"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1438",
      "neg_log_pval": 19.559482903933304,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5049092
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002429"
      ],
      "reported_trait_name": "Polycythaemia vera | non-cancer illness code, self-reported",
      "standard_trait_name": "polycythemia vera"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1438",
      "neg_log_pval": 19.559482903933304,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5063296
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004251"
      ],
      "reported_trait_name": "Myeloproliferative neoplasms",
      "standard_trait_name": "myeloproliferative disorder"
    },
    "association_info": {
      "ancestry": [
        "European=3198"
      ],
      "otg_id": "GCST002840",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002840",
      "pubmed_id": "25849990"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5063296
      },
      "alleles": {
        "reference": "G",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004251"
      ],
      "reported_trait_name": "Myeloproliferative neoplasms",
      "standard_trait_name": "myeloproliferative disorder"
    },
    "association_info": {
      "ancestry": [
        "European=3198"
      ],
      "otg_id": "GCST002840",
      "neg_log_pval": 10.0,
      "gwas_catalog_id": "GCST002840",
      "pubmed_id": "25849990"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5070831
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004251"
      ],
      "reported_trait_name": "Myeloproliferative neoplasms",
      "standard_trait_name": "myeloproliferative disorder"
    },
    "association_info": {
      "ancestry": [
        "European=3323"
      ],
      "otg_id": "GCST000357",
      "neg_log_pval": 19.397940008672037,
      "gwas_catalog_id": "GCST000357",
      "pubmed_id": "19287384"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 5070831
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004251"
      ],
      "reported_trait_name": "Myeloproliferative neoplasms",
      "standard_trait_name": "myeloproliferative disorder"
    },
    "association_info": {
      "ancestry": [
        "European=3323"
      ],
      "otg_id": "GCST000357",
      "neg_log_pval": 19.397940008672037,
      "gwas_catalog_id": "GCST000357",
      "pubmed_id": "19287384"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000096968",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 34710263
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000729"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "ulcerative colitis"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000147955",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000147955 at this locus (72455bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 34710263
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000384"
      ],
      "reported_trait_name": "Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis]",
      "standard_trait_name": "Crohn's disease"
    },
    "association_info": {
      "ancestry": [
        "European=86475"
      ],
      "otg_id": "GCST005537",
      "neg_log_pval": 8.221848749616356,
      "gwas_catalog_id": "GCST005537",
      "pubmed_id": "26974007"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000147955",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000147955 at this locus (72455bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 34889447
      },
      "alleles": {
        "reference": "G",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000270"
      ],
      "reported_trait_name": "Asthma or allergic disease (pleiotropy)",
      "standard_trait_name": "asthma"
    },
    "association_info": {
      "ancestry": [
        "European=116538"
      ],
      "otg_id": "GCST007564",
      "neg_log_pval": 10.096910013008056,
      "gwas_catalog_id": "GCST007564",
      "pubmed_id": "29785011"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000147955",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000147955 at this locus (251638bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 104902020
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "HP_0003124"
      ],
      "reported_trait_name": "High cholesterol | non-cancer illness code, self-reported",
      "standard_trait_name": "Hypercholesterolemia"
    },
    "association_info": {
      "ancestry": [
        "European=361141"
      ],
      "otg_id": "NEALE2_20002_1473",
      "neg_log_pval": 14.698970004336019,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000165029",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000165029 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 104903697
      },
      "alleles": {
        "reference": "C",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003774"
      ],
      "reported_trait_name": "Hyperlipidemia",
      "standard_trait_name": "hyperlipidemia"
    },
    "association_info": {
      "ancestry": [
        "European=408878"
      ],
      "otg_id": "SAIGE_272_1",
      "neg_log_pval": 7.73754891026957,
      "doi": "10.1038/s41588-018-0184-y"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000165029",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000165029 at this locus (0bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 120878222
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0000540"
      ],
      "reported_trait_name": "Celiac disease or Rheumatoid arthritis",
      "standard_trait_name": "immune system disease"
    },
    "association_info": {
      "ancestry": [
        "European=38053"
      ],
      "otg_id": "GCST000987",
      "neg_log_pval": 10.397940008672037,
      "gwas_catalog_id": "GCST000987",
      "pubmed_id": "21383967"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000106804",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Complement C5 inhibitor drug ECULIZUMAB is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000106804 at this locus (74113bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "9",
        "position": 130475741
      },
      "alleles": {
        "reference": "GT",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001071"
      ],
      "reported_trait_name": "Lung cancer | illnesses of father",
      "standard_trait_name": "lung carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=314072"
      ],
      "otg_id": "NEALE2_20107_3",
      "neg_log_pval": 7.955550400347374,
      "url": "http://www.nealelab.is/uk-biobank"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000097007",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Tyrosine-protein kinase ABL inhibitor drug IMATINIB is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000097007 at this locus (238206bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67291142
      },
      "alleles": {
        "reference": "G",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=1125"
      ],
      "otg_id": "GCST000250",
      "neg_log_pval": 10.301029995663981,
      "gwas_catalog_id": "GCST000250",
      "pubmed_id": "18849991"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (252890bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67343176
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=1198"
      ],
      "otg_id": "GCST001297",
      "neg_log_pval": 21.522878745280337,
      "gwas_catalog_id": "GCST001297",
      "pubmed_id": "22032556"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67343176
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=12806"
      ],
      "otg_id": "GCST001548",
      "neg_log_pval": 90.69897000433602,
      "gwas_catalog_id": "GCST001548",
      "pubmed_id": "22693459"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=13560"
      ],
      "otg_id": "GCST001148",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST001148",
      "pubmed_id": "21743467"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "High",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_IV",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_IV"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 67801708
      },
      "alleles": {
        "reference": "C",
        "alternative": "T"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0001663"
      ],
      "reported_trait_name": "Prostate cancer",
      "standard_trait_name": "prostate carcinoma"
    },
    "association_info": {
      "ancestry": [
        "European=140254"
      ],
      "otg_id": "GCST006085",
      "neg_log_pval": 9.0,
      "gwas_catalog_id": "GCST006085",
      "pubmed_id": "29892016"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Medium",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_III",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_III"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 68143959
      },
      "alleles": {
        "reference": "A",
        "alternative": "G"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004191"
      ],
      "reported_trait_name": "Male-pattern baldness",
      "standard_trait_name": "androgenetic alopecia"
    },
    "association_info": {
      "ancestry": [
        "European=43590"
      ],
      "otg_id": "GCST005116",
      "neg_log_pval": 34.52287874528034,
      "gwas_catalog_id": "GCST005116",
      "pubmed_id": "29146897"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000169083",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (413341bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 136583619
      },
      "alleles": {
        "reference": "C",
        "alternative": "A"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0002690"
      ],
      "reported_trait_name": "Pediatric autoimmune diseases",
      "standard_trait_name": "systemic lupus erythematosus"
    },
    "association_info": {
      "ancestry": [
        "European=16753"
      ],
      "otg_id": "GCST003097",
      "neg_log_pval": 8.0,
      "gwas_catalog_id": "GCST003097",
      "pubmed_id": "26301688"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000102245",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "CD40 ligand inhibitor drug DAPIROLIZUMAB PEGOL is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000102245 at this locus (64575bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 155050522
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0003827"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "pulmonary embolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000185010",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor VIII inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000185010 at this locus (23583bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  },
  {
    "sentinel_variant": {
      "locus_GRCh38": {
        "chromosome": "X",
        "position": 155050522
      },
      "alleles": {
        "reference": "T",
        "alternative": "C"
      }
    },
    "trait_info": {
      "ontology": [
        "EFO_0004286"
      ],
      "reported_trait_name": "Thrombosis",
      "standard_trait_name": "venous thromboembolism"
    },
    "association_info": {
      "ancestry": [
        "European=258962"
      ],
      "otg_id": "GCST003390",
      "neg_log_pval": 12.154901959985743,
      "gwas_catalog_id": "GCST003390",
      "pubmed_id": "26908601"
    },
    "gold_standard_info": {
      "gene_id": "ENSG00000185010",
      "evidence": [
        {
          "class": "drug",
          "confidence": "Low",
          "curated_by": "Ed Mountjoy",
          "description": "Coagulation factor VIII inhibitor drug TB-402 is Phase II for the indiciation EFO_0004286 and targets the gene ENSG00000185010 at this locus (23583bp away).",
          "source": "ChEMBL - Open Targets Evidence 19.06"
        }
      ]
    },
    "metadata": {
      "date_added": "2019-07-29",
      "reviewed_by": "Ed Mountjoy",
      "set_label": "ChEMBL_II",
      "submitted_by": "Ed Mountjoy",
      "tags": [
        "drug",
        "ChEMBL",
        "ChEMBL_II"
      ],
      "comments": "Gold-standard derived from drug-indication pairs in ChEMBL"
    }
  }
]